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ABSTRACT 
Andrew C. Hemmert 
Novel Protein-Based Solutions for Organophosphorus Nerve Agent Detection and 
Elimination 
(Under the direction of Professor Matthew R. Redinbo) 
 
 
Organophosphorus (OP) nerve agents are some of the deadliest chemicals ever 
synthesized by man.  These toxins, which include sarin, soman, cyclosarin, tabun, and 
VX, inhibit the neurotransmitter-regulating enzyme, acetylcholinesterase (AChE).  This 
leads to continual acetylcholine muscarinic and nicotinic receptor stimulus and may 
eventually result in death due to prolonged muscles contraction and diaphragm 
incapacitation.  Current treatments for OP poisoning include injections of atropine, to 
dampen acetylcholine stimulation, a strong-nucleophile oxime, such a 2-pralidoxime, to 
reactivate inhibited AChE, and diazepam for seizures.  These treatments are limited, 
however, because they do not protect against poisoning, cannot be administered prior to 
exposure, and don’t address the long-term side effects associated with nerve agent 
poisoning.  Additionally, there is no broad-spectrum oxime effective against all nerve 
agents.  A better therapeutic would be a prophylactic molecule capable of catalytically 
degrading the OP prior to AChE inhibition.   
Protein-based therapeutics are an emerging remedy for OP toxicity.  It has been 
shown that pre-administration of excess AChE in mice can protein against 8-10 normally 
lethal doses of soman.  Current enzyme therapeutics can be categorized as either 
 iv 
stoichiometric or catalytic.  Stoichiometric OP binders, such as AChE or the homologous 
butyrylcholinesterase (BChE), benefit from nanomolar (nM) dissociation constants, but 
suffer in their ability to recover after OP exposure, thereby requiring large enzyme doses 
for effective treatment.  Catalytic protein therapeutics, including serum paraoxonase  
(PON1) or the bacterial organophosphate hydrolase (OPH) exhibit rapid rates of in vitro 
nerve agent hydrolysis, but are limited by high dissociation constants, making them 
ineffective in vivo.   
Human carboxylesterase 1 (hCE1) is a liver serine hydrolase in the same !/" 
super family as AChE and BChE, which may have more favorable attributes as an OP 
bioscavenger.  Indeed rodents express a serum carboxylesterase that affords them high 
levels of protection against OPs.  Using structural and biochemical studies, we 
determined the stereopreference, rates of spontaneous reactivation, and availability of 
rapid oxime-assisted reactivation of hCE1 with nerve agents.  Next, using structurally 
guided protein design, we engineered a form of the hCE1 that combines the benefits of 
both bioscavenger classes, exhibiting nM dissociation constants and enhanced rates of 
hydrolysis, up to 48,700-fold, against the nerve agents sarin, soman, and cyclosarin.  
Finally, novel mutants of hCE1 were developed that exhibit-increased rates of 
reactivation against specific agents, and can be utilized to detect and identify chemical 
agents.   
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PREFACE 
 It was during my junior year of an undergraduate degree in chemistry at the 
University of Utah that I discovered I wanted to be a scientist.  Up until that point I had 
always enjoyed chemistry and seemed to excel in all my science classes.  At the time I 
was taking MCAT prep classes and finalizing the requirements for Medical School.  The 
thought of working tirelessly in a large concrete chemistry building wasn’t appealing.  
That fall semester, during a biochemistry lecture taught by Dr. Dale Poulter, I was 
captivated by his description of how multiple proteins function to create life.  We were 
learning about pyrimidine biosynthesis and he described how the growing substrate is 
transferred from one protein machine to another, finally creating the essential building 
block for life.  I was mesmerized with the ideas of protein nano-machines.  The thoughts 
and impressions from those lectures spilled over into the research lab where I was 
studying the expression and regulation of water channels in kidneys.  I became fascinated 
in how these tiny pores tightly regulated water during various hydration states.  Then it 
happened, I saw my first crystal structure, Aquaporin 2.  After studying the atomic 
resolution details, I came up with an idea to change this protein into a nano-machine for 
chemical transport.  Could I mutate residues within this channel to make it now selective 
for small molecules or solvents?  The ideas of creating novel proteins has been my 
obsession ever since.   
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 I was able to pursue my passion of developing novel proteins under the guidance 
of Matthew Redinbo.  Dr. Redinbo, a highly regarded scientist in X-ray crystallography 
and xenobiotic metabolism, allowed me to work on a project that utilized protein 
structure to rationally develop novel enzyme activity, or to answer the question, “Can I 
mutate these residues to make it now do this?”  The project of developing human 
carboxylesterase 1 into a nerve agent-metabolizing enzyme has been one of the most 
fulfilling pursuits of my life so far.  Not only has it enabled me to learn numerous 
scientific techniques, taught me to dissect scientific literature, and lead research groups 
from academia, industry, and government, it has allowed me to be creative and push the 
boundaries on what I thought I could do.  As a result of this project I am going to 
continue product driven research and aim to work on projects that allow me to answer the 
questions, “Can I make this protein do something new?” 
 Here I present the work completed during my graduate career under the direction 
of Dr. Redinbo.  In chapter one, I describe the history, chemical structures, and current 
treatment for organophosphorus nerve agent poisoning.  Due to the deficiencies in these 
antidotes, I will also summarize the current research on developing protein-based 
therapies, or bioscavengers, to protect against chemical agent poisoning.  In chapter two, 
I introduce the enzyme human carboxylesterase 1 (hCE1), describe how this protein 
interacts with nerve agents, and lay out the differences of this enzyme over current 
bioscavengers. In chapter three, I will present the novel mutations we introduced into 
hCE1 to generate rate enhancements in nerve agent hydrolysis by as much as 48,700-fold 
over the wild type enzyme.  I will also compare the catalytic properties of the hCE1 dyad 
mutant against other bioscavengers.  Lastly, I will discuss where this designed enzyme 
 x 
fits within the field of rational protein design.  In chapter four, I present a novel patent-
protected application that incorporates some of the mutant proteins I have generated 
during my graduate career for nerve agent detection and identification.  Finally in chapter 
five, I report other data I have generated for hCE1 mutants regarding chemotherapy 
prodrug activation and unique structural loops of this carboxylesterase compared to other 
similar enzymes.   
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Chapter 1.  Organophosphorus Nerve Agents 
 
1.1 History of Organophosphate Nerve Agents 
Organophosphate (OP) nerve agents are some of the deadliest chemicals ever 
synthesized by man.  This class of chemical agent was accidentally discovered in 1936 by 
Dr. Gerhard Schrader of I.G. Farben in Germany while attempting to develop new 
insecticides (1).  Controlled animal studies with ethyl N,N-dimethylphosphoramidocyanidate, 
now known as Tabun, reported lethality within 20 minutes of exposure.  After accidentally 
spilling a small drop on the laboratory bench, both Dr. Schrader and his assistant were the 
first human test subjects of OP poisoning, experiencing miosis and difficulty breathing that 
kept them away from the lab for 3 weeks (1).  Their discovery was reported to the Nazi 
Ministry of War and large-scale production began on this new, more deadly, chemical 
warfare agent.  In 1938 Dr. Schrader and his group discovered a second nerve agent, one that 
was 10 times more effective in animal tests as Tabun, isopropyl methylphosphonofluoridate, 
named in acronymic form after the discovering scientists as sarin (Schrader, Ambrose, 
Rudriger, and van der Linde) (2).  The additional G-agents (G for German) soman (pinacolyl 
methyl phosphonofluoridate) and cyclosarin (cyclohexyl methylphosphonofluoridate), were 
further developed in Germany during World War II (3).  Even though Nazi Germany filled 
bombs, shells, and rockets with Tabun, for differing reasons, none of these weapons were 
! "!
ever used on the battlefield.  The Allied forces only discovered these toxic agents after 
Germany was overrun (2).   
After World War II ended, the U.S., Soviet Union, and England incorporated the 
German nerve agent technology into their arsenal and began constructing weapons filed with 
sarin.  In 1952 a British scientist, Dr. Ranajit Ghosh, discovered O-ethyl S-[2-
(diisopropylamino)ethyl] methylphosphonothiolate, now known as VX, during his research 
to develop an insecticide replacement for DTT.  A derivative of this compound was briefly 
commercialized as a pesticide called Amiton, but quickly recognized as being too toxic for 
general use (1).  The secret of VX (V for venomous) nerve agent was passed to the U.S., 
where it was incorporated into ammunition and land mines, and eventually leaked to the 
Soviet Union, where additional V-agents have been developed (4).  Like Nazi Germany, the 
U.S. never released nerve agents on the battlefield, but in 1968 an accidental VX release in 
Skull Valley, Utah sickened or killed over 6000 sheep (5).  Because of this and a similar 
accident in Okinawa, Japan a year later, U.S. production of chemical agents was halted in 
1969 (1).   
Since their inception the most significant use of OP nerve agents was the Iraqi 
deployment of nerve and chemical agents against Iran during the Iran-Iraq war (6).  This was 
infamously followed in 1988 by massive Iraqi chemical agent attacks on their own people in 
Halabja resulting in over 5000 total casualties.  It is thought that tabun and sarin were 
deployed (1, 7).  Following this horrific event, many industrialized countries, including the 
U.S. and Russia, began again to produce nerve agents, focusing however on the creation of 
binary agents, or two less-than-lethal precursors, that form deadly agents when combined (1, 
4).  This escalation continued until 1993 when many countries signed the Chemical Weapons 
! #!
Convention (CWC), which banned all chemical weapon development, production, 
acquisition, stockpiling, transfer, or use and also required the destruction of existing 
stockpiles (8).   
Despite the adoption of the CWC, nerve agents are a continued threat.  There are 
reportedly more than 200,000 tons of nerve agents in existence worldwide (9).  In 1995 the 
religious doomsday cult Aum Shinrikyo attempted twice to publicly release sarin.  First they 
targeted the apartment complex of three judges who ruled against them in a land deal trial.  
During the attack, the wind changed direction and the judges were not killed, but became ill.  
Overall seven people died and 144 civilians were injured in that attempt.  More publicized 
however was their second attempt in which they released dilute sarin gas into the Tokyo 
subway system on 5 trains simultaneously.  Twelve passengers died and 5500 sought medical 
treatment (10-12).  Although these are limited examples of military and terrorist use, they 
may not accurately reflect the potential of future threats (1).      
 
1.2 Chemistry of Organophosphate Toxicology 
OP nerve agents are alkylphosphonic esters that contain different alkyl, alkoxy, and 
potent-leaving groups (Figure 1.1).  The volatility and toxicity of each agent depends on 
arrangement of these groups around the chiral phosphate (Table 1.1). Sarin is the most 
volatile nerve agent (22,000 mg/m3) compared to the volatility of VX (10.5 mg/m3) and is the 
most likely agent to exist as an actual “nerve gas” (13).  Tabun contains a cyanide leaving 
group, dimethylamine alky group, and an ester linked ethyl group.  This is the least stable 
and toxic nerve agent with a half-time of hydrolysis in water at pH 7 of 8.5 hours.    Sarin, 
soman, and cyclosarin all share common methyl alkyl and fluoride leaving groups, but differ, 
! $!
in alkoxy group; isopropyl, pinacolyl, and cyclohexyl respectively.  Soman has a half-time of 
hydrolysis of 80 hours at 20oC, pH 7 (14).  Lastly VX is composed of ethoxy, methyl, and a 
large diisopropylamino thioester leaving group.  This thioester is charged at physiological 
pH, which as discussed later, enhances the impact of this nerve agent.  VX is also the least 
volatile and most persistent of all the nerve agents, behaving similar to gasoline, and having a 
half-time of hydrolysis at 25oC and pH 7 of 30 days (14).  
Nerve agents exist in racemic mixtures, but their toxicity is greatly affected by 
stereochemistry.  The central phosphate is chiral exhibiting PR and PS isomers.  The PS 
isomers of sarin, soman, and Cyclosarin are up to 5,000-fold more toxic than the respective 
PR isomers (15).  Soman contains and additional chiral center in the pinacolyl alkoxy moiety, 
the CR enantiomer is slightly more potent than CS.  PS VX is approximately 100-times more 
toxic than the PR isomer.  
 
1.3 Mechanism of Nerve Agent Toxicity   
Nerve agents exert their toxic affects by inhibiting serine hydrolase enzymes.  The 
critical target is the neurotransmitter-regulating enzyme acetylcholinesterase (AChE) (16).  
Additional targets include butyrylcholinestease (BChE), carboxylesterases (CEs), human 
serum albumin (HSA), and serum paraoxonase (PON1) (17-19).  AChE is responsible for 
hydrolyzing acetylcholine, which transmits stimulation through muscarinic and nicotinic 
receptors in neuromuscular junctions (20).  OP nerve agents bind and covalently modify the 
catalytic serine in the enzyme’s active site.  If greater than 40% of this enzyme becomes 
irreversibly inhibited, the resulting buildup of acetylcholine will continually stimulate the 
central and peripheral nervous systems, leading to a cholinergic crisis (21).  Symptoms 
! %!
include; miosis, increased bronchial secretions and constriction, sweating, incontinence, 
tremors, convulsions, seizures, and eventually diaphragm incapacitation.  Death from OP 
nerve agents is generally attributed to respiratory failure (21, 22).  
The most common routes of OP poisoning are inhalation or dermal contact. As shown 
in Table 1.2, the LCt50, or mean lethal concentration, ranges from 50 mg-min/m3 for VX up 
400 mg-min/m3 with tabun. VX is the most toxic followed by cyclosarin, soman, sarin, and 
tabun. If percutaneous exposure occurs, again VX has the lowest LD50 (analogous to LCt50) 
at 10 mg.  This is proportional to the amount of liquid needed to fill in two columns of the 
Lincoln Memorial on a U.S. penny (7).  Cyclosarin is the next toxic with an LD50 of 30 mg, 
followed by soman (50 mg), tabun (1000 mg) and sarin (1700 mg) (13).   
 
1.4 Treatments for Nerve Agent Exposure   
Current treatments for nerve agent poisoning include injections of three different 
drugs (23).  The first, atropine is a competitive antagonist of the muscarinic acetylcholine 
receptors and reduces parasympathetic activity of all muscles and glands (24).  This tropane 
alkaloid is derived from the deadly nightshade plant (Atropa belladonna) and is a core 
medicine in the World Health Organizations “Essential Drugs List” (25).  The second drug is 
a strong nucleophile oxime, such as 2-pralidoxime (2-PAM) or obidoxime (24).  These 
molecules react with the phosphonylated catalytic serine in AChE and attempt to remove the 
covalent adduct.  This is limited in that there is no broad-spectrum oxime and reactivity 
differs for each agent (26). For example, 2-PAM is effective against sarin or VX poisoning, 
but is non-reactive with tabun, soman, or cyclosarin (26).  Additionally, if the 
phosphonylated serine has undergone a process known as “aging”, the oxime antidote is 
! &!
completely ineffective (27).  Aging is a time-dependent dealkylation of the nerve agent 
adduct.  Soman inhibited AChE has been shown to age in as quickly as 2 minutes.  The 
mechanism behind aging will be discussed in greater detail in chapter two.  Lastly, diazepam 
is given to the victim to help reduce the impending seizures associated with nerve agent 
poisoning (24).  
This treatment regimen has been utilized since the 1950’s and has several limitations 
(28).  Atropine and oximes are toxic and cannot be administered prior to exposure.  Excess 
atropine produces an effect opposite that of OP nerve agents reducing peripheral nervous 
system activity.  Patients with atropine toxicity experience dry mouth, blurred vision, 
tachycardia, increased temperature, and increased minute ventilation (29).  Besides 
reactivating inhibited AChE, oximes also affect release of acetylcholine from cholinergic 
synapses, allosterically modulate muscarinic receptors in peripheral and central synapses, and 
influence nicotinic receptor associated ion-channels (30).   
In addition to these side effects atropine, oxime, and diazepam don’t protect against 
any of the long-term side effects of OP poisoning (31, 32).  These include; anxiety, 
psychomotor depression, intellectual impairment, and sleep disturbances (21).  A review of 
manufacturer workers accidentally exposed to high doses of sarin reported high incidence of 
self-described memory disturbances, difficulty maintaining alertness, and appropriate 
focusing of attention (33).  
 
1.5 Bioscavengers 
To protect against the short- and long-term affects of nerve agent poisoning 
researchers are currently developing bioscavengers (34).  These are molecules that can be 
! '!
administered prior to exposure and could sequester the nerve agent before AChE inhibition.  
Current bioscavenger targets include monoclonal antibodies, serum AChE, plasma BChE, 
serum PON1, organophosphorus hydrolase (OPH) and CEs (16-18, 35-38).  As early as 1957 
it was observed that excess pretreatment of rats with fluorophosphatase (DFPase), an enzyme 
homologous with PON1, greater than 80% of the animals survived, whereas all the control 
unprotected rats died (39).  It has also been shown that prophylactic treatment with excess 
AChE not only protected mice against 8-10 LD50 of soman but also prevented long-term side 
effects compared to traditional oxime therapies (40).   
Current bioscavengers are either stoichiometric or catalytic (Table 1.3) (34).   
Stoichiometic binders such as AChE, BChE, and CEs act as molecular sponges binding one 
nerve agent per active site (22). Recombinant BChE is aggressively being developed for this 
purpose, including the generation of transgenic goats that secrete BChE in their milk (41, 
42).  The benefits of BChE are that it binds nerve agents with nanomolar (nM) affinity, 
exhibits stereopreferences for the more toxic PS nerve agent isomers, and has high circulation 
mean retention times (43).  AChE and BChE are non-catalytic, exhibiting spontaneous rates 
of nerve agent hydrolysis less than 1 x 10-5 min-1, therefore these stoichiometric scavengers 
would require large protein concentrations to afford effective protection.  It has been 
calculated that a dose of 250 mg BChE/70 kg person would be sufficient to protect red blood 
cell AChE above 30% after one soman LD50 (44). 
Multiple catalytic bioscavengers, such as PON1, DFPase, and OPH are being 
investigated as an alternative to stoichiometric scavengers.  If an enzyme were capable of 
efficiently hydrolyzing nerve agents, much less protein would be required.  These enzymes 
rapidly hydrolyze OP nerve agents in vitro with rates of hydrolysis as high as 840 min-1 (37).  
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Despite the enzymatic rates of hydrolysis, PON1, DPFase, and OPH suffer from high 
dissociation constants (mM range) and are ineffective in vivo (36, 37).  Additionally, these 
enzymes selectively bind and hydrolyze the less toxic PR nerve agent isomers (45).  The 
catalytic mechanisms of PON1 and DFPase are poorly understood and numerous 
investigations are underway to elucidate the residues necessary for substrate binding and 
hydrolysis (36, 46).  Recently, through rational structural design, investigators were able to 
shift the stereopreference of DFPase for cyclosarin (45). 
 Whether in military combat or targeted terrorist attacks, the threat for nerve agent 
poisoning has not diminished.  These toxins potently target AChE in neuromuscular 
junctions and may result in death through suffocation.  Current treatments for nerve agent 
poisoning are limited in that they might prevent death but provide no protection and don’t 
reduce the debilitating long-term side effects.  Novel bioscavenger therapies are currently 
being developed to sequester and detoxifying nerve agents prior to AChE inhibition.  Despite 
the respective advantages of either the stoichiometric or catalytic enzymes, they both suffer 
from limitations that prevents their incorporation as a therapeutic.  Additional work needs to 
be done on generating an efficient catalytic bioscavenger.  
 
1.6 Figures and Tables  
Figures and tables are listed in the same order they appear in the text of chapter 1. 
Figure 1.1 Chemical structures of OP nerve agents 
Table 1.1 Physical properties of OP nerve agents 
Table 1.2 OP toxicological data 
Table 1.3 Kinetic constants of current bioscavengers for soman 
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Figure 1.1 Chemical structures of OP nerve agents.  Each nerve agent is given a common 
(e.g. tabun, sarin, etc.) and NATO name (e.g. GA, GB).  Nerve agents exist as racemic 
mixtures around a chiral phosphate (*).  Soman has an additional chiral center in the 
pinacolyl alkoxy group.   
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Table 1.1 Physical properties of OP nerve agents.  They all exhibit similar properties 
except for sarin and VX.  Sarin has the lowest boiling point and is the most volatile.  This 
agent is the most likely to be present as a “nerve gas”.  VX is the most persistent OP with 
low vapor pressure and volatility.  CBWinfo.com 
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Table 1.2 OP toxicological data.  LCt50 is the lethal concentration at which a gas kills 50% 
of the exposed population.  LD50 is the percutaneous dose that will kill half the exposed 
population.  CBWinfo.com 
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Table 1.3 Kinetic constants of current bioscavengers for soman.  Acetylcholinesterase 
(AChE) and butyrylcholinesterase (BChE) are stoichiometric scavengers with nM binding 
constants (Km) but slow rates of spontaneous hydrolysis (kreact).  PON1 and OPH rapidly 
hydrolyze soman by poorly bind the substrate a(47), b(48), c(49), d(50).  
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Chapter 2.  Human Carboxylesterase 1 and Organophosphorus  
 
Nerve Agents 
 
 
2.1 Carboxylesterases and OP nerve agents 
 As previously mentioned OP nerve agents target hydrolase enzymes, covalently 
modifying the catalytic machinery within the enzyme’s active site.  AChE is the lethal target 
of OP inhibition, but other enzymes affected by nerve agent poisoning include BChE, HSA, 
PON1, and CEs (1-4).  Because of the deficiencies with current antidotal therapies, 
researchers are investigating the use of prophylactic enzymes to circulate in the blood stream 
and scavenge nerve agents before AChE is inhibited (5).  Examples of these bioscavengers 
can be observed in nature.  Rats and mice contain high levels of circulating serum CEs, that 
affords them exception protection against OP nerve agents (2).  Indeed, based on their serum 
CE levels, mice are naturally protected against up to 16 LD50s of soman compared to 
mammals that don’t express a serum CE, such as rabbits or guinea pigs (6).  In addition, 
these murine CEs exhibit 100-faster rates of spontaneous reactivation (kreact~1 x 10-3 min-1) 
for nerve agents than AChE and BChE and don’t undergo the dead-end aging process that 
plagues these cholinesterases (2, 7).  Humans don’t express a serum carboxylesterase (8), but 
based on the benefits of the rat and mouse serum CEs, the enzyme human carboxylesterase 1 
(hCE1) might be an effective bioscavenger.  
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2.2 Human Carboxylesterase 1 (hCE1) 
 hCE1 is the most highly expressed carboxylesterase in the human body (9).  This 62-
kDa enzyme is a member of the !/" serine hydrolase superfamily, and shares 33% and 34% 
homology to AChE and BChE, respectively (10).  It is primarily found in the liver, but is also 
expressed in the lung, intestine, kidneys, testes, heart, monocytes, and macrophages (11). 
Within hepatocytes, hCE1 is localized and retained in the endoplasmic reticulum a KDEL 
like retention motif (HVEL) (12).  Physiologically, hCE1 helps to regulate cholesterol by 
hydrolyzing cholesterol esters into free cholesterol prior to incorporation into extracellular 
high density lipoprotein (HDL) (9). This enzyme, also know as egasyn, and has been 
implicated in regulating C-reactive protein and "-glucoronidase release from the liver (13).  
Lastly, hCE1 is critical member of the Phase I drug metabolism pathway to hydrolyze 
compounds containing ester, thioester, and amide containing xenobiotics (9).  
The first atomic crystal structure of hCE1 was solved in 2003 in complex with 
analogs of heroine and cocaine, two substrates processed by this enzyme (14).  hCE1 shows 
an !/" hydrolase fold composed of three domains; catalytic, !", and regulatory (Figure 2.1).  
A large active site cavity is formed at the interface of these domains and contains the 
catalytic residues serine 221 (S221), histidine 468 (H468), and glutamine 354 (E354). This 
pocket is divided into two regions around S221: a large, flexible hydrophobic pocket, and a 
smaller, rigid, charged pocket.  With the assistance of an oxyanion hole, formed by three 
glycine residues (G141, G142, and G143), hCE1 utilizes the catalytic triad in a ping-pong 
mechanism to hydrolyze a variety of substrates (11).  Additional crystal structures of hCE1 
solved in complex with the Alzheimer’s drug tacrine, the cholesterol lowering drug 
! $%!
mevastatin, and the breast cancer drug tamoxifen, illustrate the promiscuous nature of this 
enzyme (15, 16). 
 
2.3 hCE1 and OP Nerve Agents 
  By definition hCE1 is a B-esterase because it is inhibited by OP nerve agents (17).  
Other B-esterases include AChE and BChE, while PON1 is an A-esterase (17).  Like AChE 
and BChE, OP nerve agents are hemisubstrates of hCE1, forming a covalent acyl-enzyme 
intermediate (Scheme 2.1).  In 2007 two atomic resolution crystal structures were solved of 
hCE1 in complex with the OP nerve agents soman and tabun (18).  In the hCE1-soman 
complex a non-aged, PR, acyl-enzyme intermediate adduct was observed, the first time this 
soman-adduct form had been seen.  In AChE and BChE soman ages rapidly and up to this 
point all other esterase-soman crystal structure were in the aged state (19, 20).  The soman 
alkoxy group was positioned in the larger, flexible binding pocket and the PR stereochemistry 
adduct suggests that hCE1 had preferentially reacted with the less toxic PR soman isomer.  
Even though a stereo-inversion occurs upon collapse of the first transition state, a change in 
priority ranking around the phosphate after leaving group dissocation, causes the same 
stereochemistry to be retained within the OP adduct (21).  In the hCE1-tabun structure a non-
aged PS isomer was observed, again implying stereopreference for the PS substrate.  
These crystal structures provided initial information about the interactions of hCE1 
and nerve agents, but they also raised a number of questions.  In both crystal structures hCE1 
had reacted with the less-toxic OP enantiomer.  Was this also the case with sarin, cyclosarin, 
and VX?  Does hCE1 exhibit an absolute steropreference for PR or PS enantiomers?  Why 
wasn’t an aged soman adduct observed in hCE1?  Is hCE1 resistant to aging?  Lastly, can this 
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human CE, like the murine CEs, spontaneous reactivate any OP nerve agents? To effectively 
gauge the ability of hCE1 to act as a bioscavenger and answer these questions, additional 
structural and biochemical experiments were necessary. 
 
2.4 Expression and Purification of hCE1  
 Before structural and biochemical studies could be pursued recombinantely expressed 
protein is required.  Purified hCE1 was produced through baculovirus mediated insect cell 
expression (14, 16, 18, 22).  This enzyme requires specific post-translational glycosylations 
that are either not made, or overly produced by more traditional expression systems such as 
Escherichia Coli (E.Coli) or Saccharomyces Cerevisiae (23).  hCE1 (GenBank accession 
NC_000016) was inserted into a pFastbac1 (Invitrogen) plasmid through ligation of a PCR 
amplification gene with sense and anti-sense primers containing EcoR1 and Pst1 restriction 
site, respectively.  The C-terminal ER retention sequence was removed during the PCR 
cloning process to enable protein secretion (23).  Following ligation, plasmids were 
transformed into DH10Bac E.Coli, where with help of the pMON7124 helper plasmid, the 
gene-encoding region is transposed via a mini-Tn7 element into the mini-attTn7 attachment 
site on the bacmid.  Utilizing the aid of antibiotic resistance and colorimetric LacZ- selection, 
recombinant bacmid DNA was isolated prior to insect cell infection.  SF21 insect cells were 
transfected with hCE1-containing bacmid via lipofectamin DNA delivery.  Three generations 
of viral titers were prepared from transfected cells in serum free media.  Each generation was 
selected for maximal protein expression through limited dilutions and hCE1 activity assays.  
Finally, secreted protein was collected 72 hours after from SF21 cells were infected with 3rd 
generation titer.  Protein expression is controlled by the multiple nuclear polyhedrosis virus 
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polyhedrin promoter and is maximally produced 30-72 hours post infection.  hCE1 was then 
purified through dialysis, isoelectric focusing, and size exclusion chromatography. 
 For smaller scale biochemical experiments hCE1 was produced by transfecting COS-
7 cells with a pCI-neo mammalian vector containing hCE1 (24, 25).  Wild type and mutant 
forms of hCE1 were ligated into pCI-neo using T4 DNA Ligase and custom sense and anti-
sense PCR primers containing EcoR1 and Sma1 restriction sites, respectively.  Prior to COS-
7 transfection, plasmids were isolated through an endo-toxin free maxiprep kit (Qiagen) and 
sequence verified (UNC genome sequencing facility). Using a Bio-Rad electroporator and a 
capacitance extender, COS-7 cells were electroporated with 20 !g of hCE1 pCI-neo plasmid 
in 200 !L PBS buffer (26).  After transfection, cells were plated on 75-cm2 flasks in fresh 
media, harvested by trypsinization after 48 hours, and frozen in liquid nitrogen.        
 
2.5 Additional hCE1-OP Crystal Structures 
 To determine crystal structures of hCE1 in complex with the sarin, cyclosarin, and 
VX, purified protein was sent to the United States Army Medical Research Institute of 
Chemical Defense (USAMRICD) where it was exposed to ~1000-fold molar excess of 
racemic respective OP agents.  After 1 hour of OP exposure, excess unbound agent was 
removed by passing the protein sample over P-10 Sephadex G-25 spin columns (GE 
Healthcare).  These DNA desalting columns have been shown to efficiently remove OP nerve 
agents (18, 22).  By measuring production of nitrophenol at 410 nm, the column eluate was 
tested to confirm that hCE1 activity had been inhibited. Uninhibited hCE1 efficiently 
hydrolyzes para-nitrophenyl butyrate (pNPB, Sigma) to form nitrophenol. To ensure that all 
excess agent had been removed, the ability of column flow-through to further inhibit BChE 
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was also measured.  Based on these two experiments we determined that hCE1 was not 
inhibited by VX.  Excess VX had been removed from the sample, and yet full enzyme 
activity remained.  Sarin and cyclosarin exposed samples were completely inhibited.  The 
thioester leaving group in VX is charged at physiological pH, poorly inhibiting hCE1.  This 
inability to interact with charged substrates is also observed in the murine serum CEs (7), 
making VX a potent cholinesterase inhibitor.  No further structural studies of VX were 
pursued.     
 Sarin and cyclosarin inhibited samples were concentrated to 3 mg/ml, and set up for 
protein crystallization using the sitting drop vapor diffusion method.  Plate like crystals (600 
!M x 100 !M x 50 !M) of hCE1-cyclosarin were grown after 8 weeks in 10% PEG 3350, 
0.3 M Li2SO4, 0.1 M Citrate pH 5.5, 0.1 M NaCl, 0.1 M LiCl, and 5% glycerol.  Despite 
multiple attempts and varying conditions, hCE1-sarin samples never crystallized.  The basis 
for these crystals not forming will be discussed later.   
 Prior to cooling to 100K for X-ray beam exposure and data collection, hCE1-
cyclosarin crystals were serially cryoprotected into a 30% sucrose plus mother liquor 
solution.  X-ray diffraction data were collected at the Argonne National Laboratory 
(Argonne, IL) on beamline 22-ID (SER-CAT).  Data were indexed and scaled using the XDS 
package (27).  Molecular replacement was conducted using MolRep in the CCP4i Suite (28) 
(v. 6.1.0) with one trimer of the hCE1-tacrine structure (RSCB PDB accession code 1MX1 
(15)) as the search model.  The hCE1-cyclosarin model was refined using rigid body, 
simulated annealing, and group B-factor refinements in CNS (29) that included an overall 
anisotropic B-factor, bulk solvent correction, and non-crystallographic symmetry (NCS) 
restraints for regions outside the active site.  Prior to any structural refinements, a subset 
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(7%) of the data were set aside for cross-validation by Rfree calculation. Manual building was 
conducted in Coot (30) with #a-weighted composite omit, difference density, and simulated 
annealing omit maps.  Data collection and refinement statistics were summarized and are 
presented in Table 2.1.  The final structure was validated using PROCHECK (31), and all 
figures were generated in PyMol (DeLano Scientific, Palo Alto, CA).  Coordinates and 
structure factors have been deposited at the PDB with accession code 3K9B. 
 
2.6 Crystal Structure of the hCE1-Cyclosarin Complex.   
The crystal structure of hCE1 in a covalent acyl-enzyme intermediate complex with 
the OP nerve agent cyclosarin was determined by molecular replacement and refined to 3.1 Å 
resolution (Table 2.1). The hCE1-cyclosarin structure was similar to ligand complexes of 
this enzyme described previously, with a root-mean-square deviation (r.m.s.d.) of 0.48 Å 
over 1,354 equivalent C! positions when compared to the hCE1-tacrine structure (15).  The 
initial maps were of good quality for the majority of the polypeptide, with the exception of 
the acyl-loop (residues 304-318) that caps the active site and five short loops (340-342, 369-
374, 406-410, 450-454, 483-488) between secondary structural elements.  When positioned 
provisionally, these disordered regions displayed B-factors of >90 Å2; in contrast, the average 
B-factor of the ordered regions of the final model was 54 Å2.  Two of these regions (369-374, 
450-454) were also disordered in the structure of a rabbit liver CE, which shares 81 % 
sequence identity and 0.42 Å r.m.s.d. over 401 equivalent C! positions relative to hCE1 (32).  
The model of hCE1 complexed with cyclosarin was refined to final R factors of 26.6% 
(Rcryst) and 29.9% (Rfree) (Table 2.1).  
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 Each hCE1 monomer, supported by two disulfide links (Cys87-Cys116, Cys274-
Cys285), contained two ligand binding sites within three domains (see Figure 2.1)(32).  The 
hCE1-trimer was formed through C3 symmetry around respective !/" domains and buries 
475 Å2 of solvent-accessible surface area per protein monomer.  The primary ligand binding 
site, the active site, was located at the interface of the three domains in each monomer as 
previously discussed.  The second ligand-binding site (or Z-site) was on the enzyme’s surface 
at the interface between the regulatory and catalytic domains. Previous crystal structures of 
hCE1 in complex with OP nerve agents soman and tabun contained sucrose, the 
cryoprotectant, in the Z-site (18).  Ser 369, which forms a hydrogen bond with the O1 of 
sucrose in these other structures, was disordered in the hCE1-cyclosarin structure and no 
ligand molecule was observed in this site. The catalytic domain also contained a high-
mannose glycosylation site at Asn79.  Density was observed near Asn79 but neither N-
acetylglucosamine nor terminal sialic acid could be reliably built and refined into this region. 
 As outlined in Scheme 2.1 cyclosarin inhibits hCE1 by forming a covalent adduct 
with the catalytic serine.  In the structure of the hCE1-cyclosarin complex, a covalent 
cyclosarin adduct was easily identified in initial difference density (F0 ! Fc ) maps as a 6 ! 
electron density peak approximately 1.6 Å away from the S221 O$, which corresponded to 
the nerve agent phosphate.  At lower ! levels (2.5-4 !), additional density for the complete 
molecule was apparent.  The cyclosarin model was built into the observed density, refined, 
and PR stereochemistry was assigned around the chiral phosphate (Figure 2.2). The acyl-
enzyme adduct was stabilized by two hydrogen bonds.  These occur between the cyclosarin 
phosphoryl oxygen atom and hydrogen atoms present on the amide nitrogens of the oxyanion 
hole (2.6 Å and 2.4 Å, respectively).  The O-cyclohexyl alkoxy group is located within in the 
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larger, flexible pocket of the active site and is stabilized by interactions with Leu363 of the 
regulatory domain. The stereochemistry and alkoxy placement was confirmed with a 3.1 Å 
resolution simulated annealing omit map, contoured to 5 # (Figure 2.3).  The opposite PS 
isomer was also built into the starting model and one round of refinement was performed.  
Clear positive and negative density from a difference density map ( F0 ! Fc ,"calc ) verified the 
PR assignment as consistent with the biochemical results (Figure 2.4). 
 This is the first crystal structure of any protein covalently bound to cyclosarin and as 
with the previous hCE1 OP crystal structures, the hCE1-cyclosarin structure is in a non-aged 
state and bound to the less-toxic PR isomer. This bulky cyclohexyl group is positioned 
towards the large, flexible pocket in the active site.  The smaller, rigid pocket cannot 
accommodate this large alkoxy group, a requirement for PS binding.  To confirm the 
observed OP stereoprefence and understand the binding affinity of hCE1 for PR and PS nerve 
agent isomers, the bimolecular rates of inhibition for nerve agents with hCE1 were 
determined. 
 
2.7 Bimolecular Rates of Inhibition for OPs in hCE1   
Sarin, soman, and cyclosarin contain a chiral phosphorus atom and exist as racemic 
mixtures of PR and PS stereoisomers.  Soman also has an asymmetric carbon (C!) in the 
pinacolyl group.  The PS isomers of sarin, soman and cyclosarin inhibit AChE more potently 
than the PR forms; for example, the preference of PS vs. PR soman is 5,000-fold for AChE 
(33).  Using OP nerve agent analogs containing a thiomethyl-leaving group prepared as 
purified stereoisomers (Figure 2.5), we determined the stereoselectivity of hCE1 inhibition 
by analogs of sarin, soman, and cyclosarin (Figure 2.6). These analogs have been shown by 
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MALDI-TOF mass spectrometry to yield, among other products, acyl-enzyme adducts 
identical to those from authentic agents when used to inhibit BChE (34).  The thiomethyl-
leaving group that replaces the fluoride atom decreases the toxicity of the analogs by slowing 
the rate of phosphonylation (k2) compared to bona fide agents; however, the dissociation 
constants (Kd) remain similar (35).  The decrease in k2 results in a reduction in the 
bimolecular rate of inhibition (ki) by 2-3 orders of magnitude when compared to the 
corresponding nerve agent (6).  
Samples of purified hCE1 at 100 nM were inhibited at room temperature with 
increasing concentrations of stereogenic OP nerve agent analogs.  Aliquots of enzyme 
incubated with stereoisomer analogs of sarin (PR, PS), PS soman, and PS cyclosarin were 
removed at various time points (up to 1 hr) and the level of active enzyme that remained was 
determined by comparing pNPB hydrolysis relative to an uninhibited sample.  Because the 
PR soman and PR cyclosarin analogs react more quickly with hCE1, the impacts these analogs 
had on hCE1 were measured continuously (for up to 15 min) by adding increasing 
concentrations of analog to enzyme samples containing pNPB and measuring loss of 
functional activity over time.  These data, collected at 410 nm and 25 oC on a Pherastar 
microplate reader (BMG Labtech), were corrected for spontaneous pNPB hydrolysis and fit 
to equation 1 (36):   
!t
! lnv =
Kd
k2
* 1[IX](1"# ) +
1
k2
       (1) 
where Kd was the dissociation constant, k2 the unimolecular phosphorylation rate constant, v 
the remaining percent enzyme activity, [IX] was the OP analog concentration, ! was 
[S] / (KM + [S]) , in which [S] was the substrate concentration and KM was the Michaelis-
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Menton constant.  All experiments were performed in triplicate.  Data were analyzed in 
KaleidaGraph 4 (Synergy Software, Reading, PA) to determine ki (ki = k2 / Kd) values.  
PR analogs of soman and cyclosarin inhibited hCE1 1,700- and 2,900-fold more 
efficiently than the PS isomers, respectively. In contrast, hCE1 exhibited a 5-fold preference 
for the PS vs. PR form of the sarin analogs.  This strong hCE1 preference for the PR isomers of 
cyclosarin and soman analogs is opposite to the stereopreference observed for AChE with 
bona fide nerve agents.  A structural comparison of the hCE1-soman and hCE1-cyclosarin 
crystal structures with AChE-soman (RSCB PDB code 2WGO (33)) reveals that the bulky PR 
O-alkoxy group is positioned into the larger hydrophobic binding pocket of hCE1.  In 
contrast, this region is occupied in AChE by a long acyl loop that dips into the active site 
pocket and precludes binding of PR nerve agents (18, 33).  Therefore, the geometry of the 
hCE1 active site size dictates the enantiomeric binding of the bulkier nerve agents soman and 
cyclosarin.  
With the smaller nerve agent sarin, hCE1 demonstrated only a 5-fold preference for 
the PS isomer of the sarin nerve agent analog.  Our structures indicate that while both isomers 
of sarin will fit in the active site of the enzyme, only PS sarin is capable of forming stabilizing 
hydrophobic contacts with Phe101 and Leu97; PR sarin would not form analogous 
interactions (Figure 2.7).  These structural considerations, in part, explain the observed 
strong preference for PR soman and cyclosarin, and the relatively weak preference for PS 
sarin exhibited by hCE1. Taken together, these results demonstrate that hCE1 exhibits a 
strong preference for the PR soman and cyclosarin analogs, and a smaller preference for the 
PS isomer of the smaller, sarin analog. 
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2.8 Spontaneous Nerve Agent Reactivation in hCE1 
 After the formation of the acyl-enzyme intermediate, proteins exposed to OP nerve 
agents may remain stably adducted, permanently inhibited (aged), or undergo spontaneous 
hydrolysis (hereafter referred to as reactivation) reversing the phosphonylation and returning 
the enzyme to normal function (37, 38) (Scheme 2.2). To test the ability of hCE1 to 
reactivate after inhibition by nerve agents, the enzyme was challenged with racemic mixtures 
of the OP nerve agents soman, sarin, and cyclosarin.  Fifty !L of COS cell lysate expressing 
a non-secreted form of hCE1, prepared as previously described (24), was inhibited with a 
~1000- fold molar excess of racemic OP agents sarin, soman, or cyclosarin for 10 min.  
Excess agent was removed by passing inhibited samples over a PD-10 Sephadex G-25 size 
exclusion column (GE Healthcare).  The column eluate was diluted 10-fold in 0.1 M 
potassium phosphate buffer, pH 7.4 and tested for the presence or absence of CE activity and 
complete removal of excess agent, as previously described. Aliquots were removed over time 
(up to 80 hrs) and the percent enzyme activity was measured by pNPB hydrolysis relative to 
an uninhibited sample.  The rate of reactivation (kobs) and maximal percent recovery (Amax) 
were determined by fitting the data to equation 2: 
A = A0 + Amax (1! e!kobst )         (2) 
where A was percent activity at time, t, and A0 was initial activity at t=0.  The experiments 
were conducted in triplicate and data were analyzed with Sigma Plot v.8.02 (Systat, Chicago, 
IL). 
We found that only samples inhibited with sarin exhibited spontaneous reactivation 
(Figure 2.8), with a half time of 45 hours (kobs=2.58 ± 0.06 x 10-4 min-1).  When carried out 
to 300 hours, a maximum activity of 84 ± 6% was recovered (Figure 2.9).  The rate of 
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reactivation was approximately 10-fold slower than that measured for rat serum CE (2), but 
10-fold faster than BChE (39).  In contrast, AChE exhibits no reactivation following sarin 
inhibition (39).  hCE1 inhibited with soman and cyclosarin, however, exhibited poor 
reactivation and achieved a maximum recovery of activity of only ~10% even after 300 
hours. These data establish that reactivation of hCE1 only occurs following exposure to sarin, 
and explain why no hCE1-sarin crystals formed.  hCE1 requires a substrate in the active site 
for crystal formation and by the time samples were returned to UNC-CH for crystallization 
most of the sarin had already been hydrolyzed.    
 
2.9 Oxime Assisted Reactivation in hCE1 
 An alternative mechanism for nerve agent reactivation is through oxime assistance. 
Strong oxime nucleophiles like 2-PAM and obidoxime are known to reactivate OP-inhibited 
esterases, particularly AChE, by promoting the dephosphonylation of the active site serine. 
These cationic oximes are currently used as part of post-exposure therapy and are appropriate 
for the anionic choline binding gorge in cholinesterases (40).  Carboxylesterases such as 
hCE1 react poorly with charged substrates (7);  however, the ability of a neutral oxime like 
diacetyl monoxime (DAM) to reactivate inhibited hCE1 had not been reported in the 
literature.  Thus, we tested whether DAM would reactivate hCE1 that had been exposed to 
racemic nerve agents or stereogenic nerve agent analogs.  The combination of oximes and 
stoichiometric bioscavengers had been utilized to make a pseudo-catalytic bioscavenger (3).  
 Fifty !L of COS cell lysate containing hCE1 were inhibited and excess agent was 
removed as previously described.  The OP analogs were utilized in a similar fashion to 
racemic nerve agents, but required a longer incubation time (up to 1 hr).  Upon column 
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elution, samples were diluted 10-fold into 1 mM DAM (Sigma), which had been previously 
prepared in 0.1 M potassium phosphate pH 7.4 and kept on ice.  DAM had no inhibitory 
effect on hCE1 at this concentration.  Aliquots were removed over time and enzyme activity 
was measured as described above.  The rates of reactivation (kobs) and maximal percent 
reactivation (Amax) were determined for each agent/analog by subtracting background oxime-
induced pNPB hydrolysis and fitting the data to equation 2.  
We found that DAM enhanced the reactivation of sarin-inhibited hCE1, but not 
enzyme inhibited by soman or cyclosarin (Figure 2.10 A).  In the presence of DAM, sarin-
inhibited hCE1 exhibited a half time of reactivation of 41 minutes (kobs=0.0168 ± 0.0003 min-
1 mM-1), approximately 66-fold faster than that observed without the oxime (see Figure 2.8).  
In addition, similar to spontaneous reactivation, the maximal recovery of hCE1 that was 
observed in the presence of DAM was 89 ± 4%.  Thus, the neutral oxime DAM increased the 
rate of reactivation of sarin-inhibited hCE1 by more than 65-fold.   
We next examined the ability of DAM to enhance the reactivation of hCE1 inhibited 
with pure enantiomeric PR or PS isoforms of the nerve agent analogs (see Figure 2.5).  We 
found that hCE1 inhibited with the PS sarin analog exhibited reactivation with a half-time of 
30 minutes (kobs=0.023 ± 0.004 min-1 mM-1), while hCE1 inhibited by the PR sarin analog 
exhibited no detectable reactivation (Figure 2.10 B).  In contrast, hCE1 samples inhibited 
with PS soman and cyclosarin analogs were capable of marginal reactivation, while 
respective PR analogs displayed no recovery (Figures 2.10 C and 2.10 D).  Taken together, 
these data suggest that the reactivation of hCE1 in the presence of the sarin analog was due to 
the hydrolysis of the PS isomer, while the PR isomer cannot be removed from the active site 
even in the presence of DAM.  
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2.10 Aging in OP-inhibited hCE1   
The alternative end result to reactivation after acyl-enzyme intermediate formation is 
aging (see Scheme 2.2).  Aging in serine hydrolases involves the time-dependent 
dealkylation of the bound adduct, resulting in a permanently phosphorylated catalytic serine 
residue (37). This process is rapid for soman in the active site of AChE (t1/2 of ~2 minutes), 
and is the primary cause of the toxicity of this agent (33). Once aging has occurred, nerve 
agent adducts are inert even to strong oximes.  We explored the propensity of hCE1 to age in 
the presence of nerve agent analog PS stereoisomers by measuring the loss in the maximal 
level of DAM-mediated reactivation (Amax) over time.  
Samples of 1 !M purified hCE1 were inhibited with a 1,000-fold molar excess of the 
PS sarin, soman, and cyclosarin analogs for 60 minutes at room temperature.  Complete 
inhibition was verified by the absence of pNPB hydrolysis.  Excess unbound agent was 
removed by size exclusion chromatography as previously described, and aliquots were 
diluted 1:10 into 1 mM DAM every 12 hours for 48 hours.  After dilution into DAM, each 
sample was incubated for 24 hours to achieve maximal DAM-assisted reactivation, and then 
enzyme activity was measured and percent reactivation was determined relative to an 
uninhibited sample.  Maximum percent reactivation (Amax) was plotted against the incubation 
time in the absence of DAM and fit to equation 3 (41): 
Amax = Amax0 exp-ka t          (3) 
where Amax0 was the maximum recovery at time=0, and ka was the rate of aging.   
If the nerve agent analog adduct undergoes time-dependent dealkylation, one would 
expect an exponential decay for Amax (41). Over 48 hours, no change in Amax was observed 
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for any of the agent analogs (Figure 2.11).  For example, after two hours exposure of hCE1 
to the PS sarin analog, DAM was capable of reactivating ~60% of the enzyme activity (see 
Figure 2.10 B); however, even after 46 additional hours of incubation with this sarin analog, 
the same fraction of enzyme activity, recovered by DAM, was observed (Figure 2.11).  
Thus, sarin-inhibited hCE1 does not appear to undergo the same first-order aging process that 
has been observed with AChE and BChE.  hCE1 and rat serum CE do not contain three 
specific residues essential for aging in the cholinesterases, thereby limiting the potential for 
this dead-end process (2).       
  
2.11 Mechanism for Sarin Reactivation in hCE1 
These data clearly show that hCE1 is able to reactivate, either spontaneously or 
oxime-assisted, following sarin inhibition.  Additionally, it is clear that only the PS isomer is 
being hydrolyzed to reactivate the enzyme.  Finally, this isomer does not undergo that dead-
end aging process observed in AChE and BChE.  Using these data and prior literature we 
generated a model to explain how hCE1 might preferentially reactivate PS sarin (Figure 
2.12). Early work investigating the influence of pH on spontaneous reactivation in AChE 
identified the importance of two ionizable residues with pKa values of 6.9 and 9.8, 
suggesting possible His and Tyr residues, respectively (42).  In the hCE1 active site, the 
catalytic His468 neighbors PS sarin and Tyr152 is located approximately 8 Å away.  These 
two residues are connected via a hydrogen-bonding network through Glu200 (Figure 2.12). 
It has been observed in the structure of the AChE covalent complex with non-aged PS VX 
that the protonated N%2 of His440 (H468 in hCE1) rotates away from Ser200 (Ser221 in 
hCE1) to form a hydrogen-bond with Glu199 (Glu220 in hCE1) (20).  The N%2 movement 
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would be expected to be blocked in hCE1 by larger alkoxy groups, such as the O-pinacolyl 
group in soman, and is not observed in a non-aged AChE soman structure (33).  If this shift 
occurs in hCE1 with PS sarin, however, the His468 N%2 rotation to Glu220 would reorient the 
remaining His468 nitrogen, N&1, formerly hydrogen-bonded to Glu354.  It would then be 
positioned to interact with the PS sarin O2 atom and may act as a general base for hydrolytic 
dephosphonylation (Figure 2.12).  An analogous orientation of the O2 atom of PR sarin 
would not be possible while still maintaining interactions with the oxyanion hole (see Figure 
2.7).  By this model, hCE1 will only reactivate after inhibition with PS sarin, consistent with 
the experimental results presented above.  However, the rate of reactivation is observed to be 
poor, likely due to the weak nucleophilicity of Tyr152 at pH 7.4.   
Finally we considered what the fate of the PR-hCE1 adducts are if they do not age, 
and the state of the remaining percent of PS-hCE1 adducts that do not undergo reactivation.  
For complexes of PR organophosphates and hCE1, we propose that they remain at the acyl-
enzyme intermediate stage of the enzyme’s reaction mechanism. This state has been 
observed in the hCE1-PR soman and hCE1-PR cyclosarin crystal structures, and via MALDI-
TOF analysis of BChE inhibited by PR analogs of sarin, soman, and cyclosarin (34).  For the 
40% of PS-sarin analog complexes with hCE1 that do not undergo reactivation, we propose 
that an alternate S221 state is created. In addition to forming adducts identical to authentic 
agents, the thiomethyl-nerve agent analogs utilized in this study have been shown to undergo 
a unique reaction, where the O-alkoxy rather than the thiomethyl group is displaced upon 
collapse of the original pentahedral intermediate (34).  Therefore, dehydroalanine formation 
at the catalytic serine might also occur with these nerve agent analogs.  Mass spectrometry 
studies were attempted to confirm or deny the presence of this adduct in hCE1; 
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unfortunately, the peptide fragment containing S221 could not be isolated and no useful data 
were obtained (personal communication with Dr. Oksana Lockridge).   
 
2.12 Summary of hCE1 and Nerve Agents 
These studies establish the stereopreference of wild type hCE1 for nerve agent 
analogs of cyclosarin, soman and sarin, and confirm this preference for cyclosarin with 
crystallographic data.  Unfortunately, wild type hCE1 exhibits opposite stereoprefence to 
AChE for soman and cyclosarin.  These data reveal that the native form of hCE1 is capable 
of reactivation after incubation with the nerve agent sarin, and that the rate of reactivation is 
enhanced with the neutral oxime DAM.  Lastly, hCE1 does not undergo the dead-end aging 
process observed with the cholinesterases.  The ability to spontaneously reactivate the more 
toxic form of sarin and not age in the process qualifies hCE1 as a stronger bioscavenger 
candidate against this agent than the other stoichiometric scavengers.  These data are 
published in molecular pharmacology (22). In Chapter 3, I will present how we used these 
data to design mutant forms of hCE1 with enhanced rates of nerve agent hydrolysis for not 
only sarin, but also soman and cyclosarin.  
 
2.13 Figures and Tables  
Figures and tables are listed in the same order they appear in the text of chapter 2. 
Figure 2.1 hCE1 monomer 
Scheme 2.1 Chemical scheme of hCE1 reacting with cyclosarin 
Table 2.1 Crystallographic data collection and refinement statistics 
Figure 2.2 hCE1-cyclosarin complex 
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Figure 2.3 hCE1-cyclosarin adduct stereochemistry  
Figure 2.4 Incorrect hCE1-cyclosarin adduct stereochemistry  
Figure 2.5 Organophosphate nerve agent analogs.  
Figure 2.6 Bimolecular Rates of Inhibition for hCE1 and nerve agent analogs  
Figure 2.7 hCE1-sarin model 
Scheme 2.2 Aging and hydrolytic pathways of serine hydrolases 
Figure 2.8 Spontaneous reactivation of racemic bona fide OP nerve agents by hCE1  
Figure 2.9 Maximal reactivation of racemic bona fide nerve agents by hCE1   
Figure 2.10 DAM assisted reactivation after inhibition by racemic bona fide OP Nerve agents 
or stereospecific nerve agent analogs  
Figure 2.11 Determination of aging with PS nerve agent analogs in hCE1   
Figure 2.12 Model for spontaneous reactivation of PS sarin by hCE1 
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Figure 2.1 hCE1 monomer. Each protein monomer has three domains; the !/" domain 
(blue) forms the trimer interface and caps the active site, the regulatory region (orange) 
contains the secondary surface binding site (Z-site) and Glu354 of the catalytic triad, and the 
catalytic domain (green) contains the central "-sheet conserved in serine hydrolases, as well 
as the two catalytic residues His468 and Ser221. There are two disulfide bonds (cyan), one in 
the !/" domain and the other in the catalytic domain, and one glycosylation site, at Asn79 
(yellow). 
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Scheme 2.1 Chemical scheme of hCE1 reacting with cyclosarin.  Glu354 (not shown) 
deprotonates N&1 of His468, causing N%2 to deprotonate Ser221, enabling nucleophilic 
attack on the phosphonyl center.  After collapse of the pentahedral transition state, a stable 
covalent acyl-enzyme intermediate is formed. 
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TABLE 2.1 Crystallographic data collection and refinement statistics. 
aNumber in parenthesis is for the highest shell.   
b Rsym = '|I - "I#|' I, where I is the observed intensity and "I# is the average intensity of 
multiple symmetry-related observations of that reflection.   
cRcryst = ' ||Fo| - |Fc|| / '|Fo|, where Fo and Fc are the observed and calculated structure factors, 
respectively.  
dRfree = ' ||Fo| - |Fc|| / '|Fo| for 7% of the data not used at any stage of structural refinement. 
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Figure 2.2 hCE1-cyclosarin complex.  Cut away view of the hCE1-cyclosarin active site.  
The catalytic triad and cyclosarin molecule are shown in purple, oxyanion hole in white, and 
the surrounding residues in green.  Hydrogen bonds between the phosphoryl oxygen and the 
backbone nitrogen atoms in the oxyanion hole are shown in red. 
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Figure 2.3 hCE1-cyclosarin adduct stereochemistry. S221 and H468 of the catalytic triad 
and the cyclosarin adduct are shown in purple.  The oxyanion hole is colored white.  
Stereoview of a 3.1 Å resolution Fo – Fc simulated annealing omit map (blue, contoured to 5 
#) calculated for the PR-cyclosarin adduct. 
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Figure 2.4 Incorrect hCE1-cyclosarin adduct stereochemistry. Stereoview of initial 
difference density maps for the incorrect PS-cyclosarin adduct (green for positive, shown at 3 
#; red for negative, shown at -3 #).!
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Figure 2.5 Organophosphate nerve agent analogs. Nerve agents contain a methyl, O-
alkoxy, and good leaving group built on a central chiral phosphonate.  The stereogenic OP 
nerve agent analogs contain a thiomethyl leaving group in place of the fluoride. 
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Figure 2.6 Bimolecular rates of inhibition for hCE1 and nerve agent analogs. Plotted as 
log ki, hCE1 exhibits strong enantiomeric PR preference for soman and cyclosarin analogs, 
with only slight PS sarin analog selectivity.  Dissociation constants (Kd) are similar to 
authentic nerve agents, while phosphorylation rates (k2) are 2-3 orders of magnitude slower. 
N=3, S.E. 
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Figure 2.7 hCE1-sarin model.  PR and PS enantiomers of sarin modeled in the hCE1 active 
site.  The O-isopropyl group on PS sarin makes hydrophobic contacts with Phe101 and 
Leu97, while PR does not have any additional interactions. 
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Scheme 2.2 Aging and hydrolytic pathways in serine hydrolases. 
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Figure 2.8 Spontaneous reactivation of racemic bona fide OP nerve agents by hCE1.  
Reactivation on occurs against sarin (!), with a half-time of reactivation of ~45 hours.  
Soman (") and cyclosarin (#) inhibited samples exhibit no reactivation.   
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Figure 2.9 Maximal reactivation of racemic bona fide nerve agents by hCE1.   
After 300 hours, sarin (!) inhibited samples are reactivated to 89 ± 5%, while soman (") and 
cyclosarin ($) inhibited samples remain permanently inhibited.   
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Figure 2.10 DAM assisted reactivation after inhibition by racemic bona fide OP nerve 
agents or stereospecific nerve agent analogs. A) Reactivation with racemic bona fide nerve 
agents.  Recovery is only measured against sarin (!) with a half-time of reactivation of 41 
minutes (N=3, S.E.).  Soman (%) and cyclosarin ($) did not reactivate.  B) Reactivation of 
sarin analogs. The PS isomer (!) reactivates with a half-time of 30 minutes (N=3, S.E.).  PR 
sarin (&) analog did not reactivate. C) Reactivation of soman analogs.  Greatest recovery 
was measured in the PS (') enantiomer, while the PR (%) analog remained inhibited. D) 
Reactivation of cyclosarin analogs.  Negligible recovery was measured for either PS (!) or 
PR ($) cyclosarin analog. 
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Figure 2.11 Determination of aging with PS nerve agent analogs in hCE1.  No aging was 
measured for the PS species.   
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Figure 2.12 Model for spontaneous reactivation of PS sarin by hCE1. In AChE, H468 has 
been observed to rotate away from E354 and interact with E221 after acylation.  Modeling 
this shift in the hCE1 active site, there is an electronic network formed between Y152 (green) 
and H468 (yellow) that may either deprotonate N%2 or allow N&1 of H468 to act as a general 
base for water activation.  PS sarin (blue) was modeled into the hCE1-soman structure (RSCB 
PSB access code 2HRQ (18)).!!
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Chapter 3.  Structurally Guided Design of Human 
Carboxylesterase 1 into a Nerve Agent Hydrolyzing Enzyme 
 
3.1 Catalytic Complication of OP Nerve Agents in hCE1 
Human carboxylesterase 1 (hCE1) is a promiscuous liver hydrolase involved in the 
metabolism of compounds ranging from endobiotics like cholesteroyl esters to xenobiotics 
like pyrethroid pesticides or chemotherapy prodrugs.  It has been postulated that broad-
spectrum, generalized enzymes are evolutionary intermediates to specialized enzymes (1).  
Perhaps through structurally guided design, nerve agent hydrolysis activity can be engineered 
to compliment the predisposition of hCE1 to bind organophosphates.  To understand how the 
protein can be modified for enhanced nerve agent hydrolysis, the limitations of the wild type 
enzyme need to be addressed.   
hCE1 uses a serine catalytic triad to hydrolyze ester, thioester, and amide bonds (2).  
As illustrated in Figure 3.1, H468 forms a hydrogen bond at N!1 with E354, thereby 
polarizing and enabling the lone pair of electrons on N"2 to deprotonate S221.  S221 then 
acts as a nucleophile to attack the carbonyl center of an ester substrate.  A tetrahedral 
transition state forms, which collapses to release an alcohol, resulting in an acyl-enzyme 
intermediate.  The high pKa of the alcohol leaving group (pKa ~15) depronotates 
neighboring H468, enabling this catalytic base to activate a water molecule for hydrolysis.  
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The newly formed hydroxide ion can now attack the carbonyl center of the acyl-enzyme 
intermediate, forming a second tetrahedral transition state, which upon collapse cleaves the 
S221-substrate ester bond, regenerating the enzyme for another round of catalysis.  Catalytic 
triads are one of the most efficient mechanisms for hydrolyzing substrates.  Indeed, 
acetylcholine hydrolysis by AChE is one of the fastest known enzyme reactions (3).   
 The catalytic complication with nerve agents occurs after the first transition state 
(Figure 3.2) (4).  As the pentahedral transition state collapses, the nerve agent leaving group, 
which has a much lower pKa than a conventional alcohol, dissociates but likely leaves H468 
protonated.  For example fluoride, the leaving group in sarin, soman, and cyclosarin, has a 
pKa of 4.  The drastic difference in the chemical nature of the dissociating groups halts the 
mechanism since a catalytic base is not available for water activation (5). We hypothesized 
that if an additional base could be added into the hCE1 active site for water activation, 
enzyme function towards OPs could be enhanced.   
Using the crystal structures of hCE1 in complex with soman and cyclosarin (RCSB 
PDB 2HRQ and 3K9B, respectively (6, 7)), we explored the active site for positions where a 
histidine or glutamic acid could be added.  Histidine has a pKa of 6 and can act as both an 
acid or base at physiological pH, while Glu or Asp serves as the base in protein tyrosine 
phosphatases to efficiently hydrolyze phosphorylated substrates (8).  As shown in Figure 
3.3, residues V146 and L363 were selected based on their location above the acyl-enzyme 
intermediate for an SN2 hydrolytic attack.  In order to cleave the S221-OP phosphate bond, a 
water molecule would need to approach in-line with these atoms.  
 
3.2 Site-directed mutagenesis of hCE1 
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Site-directed mutagenesis was utilized with custom-designed primers to introduce 
single mutations at positions 146 and 363.  Primers are listed in Table 3.1.  Briefly, 
mutations were introduced in the hCE1 gene (GenBank accession code NC_000016) 
contained within the ampicillin resistant pUC9 plasmid through 15 rounds of PCR with 
respective primers.  After PCR, template plasmids were digested for 1 hr at 37oC with Dpn1 
(Fermentas Life Sciences), transformed into DH5# cells, and colonies were grown overnight 
on ampicillin resistant plates.  Single colonies were selected and further grown in LB 
suspension. Plasmids were then isolated and successful mutant incorporation was verified by 
DNA sequencing.  To express mutant hCE1 in COS cells, the modified hCE1 gene was 
cloned into the mammalian expression vector, pCI-neo (Promega, Madison, WI).  Briefly, 
using 30 rounds of PCR and custom designed 5’ and 3’ primers with flanking engineered 
EcoR1 and Sma1 (Fermentas Life Sciences) restriction sites, the 1.7 kb hCE1 gene was 
cloned out of pUC9 and ligated into the 5.4 kb pCI-neo using T4 DNA ligase.  hCE1-
containing plasmids were selected and isolated from colonies that incorporated successful 
ligations, then verified through Pst1 (Frementas Life Sciences) digestion to confirm presence 
of gene in plasmid, followed by DNA sequencing.  Endotoxin free (Quaigen) pCI-neo 
plasmids were then prepared and transfected into COS cells through electroporation as 
described in Chapter 2.4.   
 
3.3 Spontaneous Reactivation of hCE1 mutations following nerve agent inhibition 
    In collaboration with the United Stated Army Medical Research Institute of 
Chemical Defense (USAMRICD) we tested over 50 designed mutants of hCE1 for 
spontaneous reactivation following sarin, soman, cyclosarin, or tabun inhibition.  As reported 
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is Chapter 2.8, wild type hCE1 spontaneously reactivates following sarin inhibition, with a 
half-time of reactivation of ~45 hours (7), but remains permanently inhibited after soman, 
cyclosarin, and tabun exposure.  Fifty !L of mutant hCE1 COS cell lysate was incubated 
with ~1000-fold molar excess of sarin, soman, cyclosarin, or tabun for approximately 10 
minutes.  Complete inactivation was verified by comparing the ability of the inhibited sample 
to hydrolyze 10 mM pNPB relative to an unexposed sample.  All mutant enzymes were still 
capable of hydrolyzing pNBB (data not shown).  Excess agent was removed by passing the 
sample over a PD MiniTrap G-25 desalting spin column (GE Healthcare) and eluate was 
diluted 1:10 into 100 mM phosphate buffer pH 7.4.  Samples were then verified for complete 
agent removal by measuring the ability of flow-through fractions to further inhibit BChE.  
Rates of spontaneous reactivation (kobs) and maximal percent reactivation (Amax) were 
determined by measuring the ability of nerve agent inhibited samples to hydrolyze pNPB 
compared to an uninhibited sample and fitting the data to equation 1: 
        (1) 
where A was percent activity at time, t, and A0 was the initial activity at t=0.  The 
experiments were conducted in triplicate and data were analyzed with KaleidaGraph 4 
(Synergy Software, Reading, PA).  pNPB is a conventional ester substrate and hydrolysis is 
measured by following absorbance of o-nitrophenol at 410 nm on a microplate reader. 
    As shown in Figure 3.4, the designed dyad hCE1 mutant V146H/L363E was able 
to rapidly reactivate following inhibition by racemic sarin, soman, and cyclosarin.  
V146H/L363E remained inhibited after tabun exposure.  This mutant completely hydrolyzed 
cyclosarin, with a half-time of reactivation of 68 ± 4 minutes at pH 7.4 and 25oC, and 
returned to >90% uninhibited activity following sarin and soman inhibition with a half-times 
 A = A0 + Amax (1- e
-kobs t )
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of reactivation of 9 ± 1 hours and 11 ± 3 hours, respectively.  This is the fastest reported rate 
of cyclosarin hydrolysis by a mutant esterase. A mutant form of BChE (G117H/E197Q) has 
been generated that reactivates following racemic soman inhibition, with a half-time of 
reactivation of 1.9 ± 0.2 hours (9).  As mentioned in Chapter 2.8, wild type hCE1 cannot 
reactivate following cyclosarin or soman exposure.  
 
3.4 Mutant controls of nerve agent hydrolysis 
 To understand the combination of V146H/L363E for cyclosarin hydrolysis we made 
control mutants and tested them for spontaneous reactivation following exposure to racemic 
sarin, soman, or cyclosarin.  Figure 3.5 reports the rates of spontaneous reactivation for each 
control mutant.  V146H and L363Q enhance the rates of sarin hydrolysis, but their 
combination is less than additive, suggesting that these residues are not interacting in a 
functional manner.  These mutants have no effect on cyclosarin hydrolysis.  Soman 
hydrolysis is fastest with V146H but only recovers to approximately 10% uninhibited 
activity.  The V146H/L363E mutant is almost as rapid as V146H against soman, but recovery 
is increased to 90 ± 3 %.  L363E alone exhibits slight sarin and soman hydrolysis, but is most 
effective for cyclosarin (half-time of reactivation of 7 ± 1 hours).  Adding V146Q to L363E 
further reduces the half time of cyclosarin hydrolysis to 3 hours, perhaps by positioning the 
carboxylate head group, but does little for sarin or soman reactivation.  Only the synergistic 
mutant V146H/L363E is capable of rapidly reactivating after cyclosarin inhibition, and 
recovering near full activity following sarin and soman inhibition.  
Tables 3.2-3.4 report the rates of spontaneous reactivation (kreact) and percent 
maximal recovered activity (Amax) for V146H, V146Q, L363E, L363Q, V146H/L363Q, 
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V146Q/L363E, and V146H/L363E hCE1 mutants towards sarin, soman, and cyclosarin.  To 
emphasize the impact of each mutant we devised an adjusted rate of reactivation (Adjusted 
kreact = (kreact!Amax) / 100), which combines the rates of reactivation and percent maximal 
activity into one term.  An ideal bioscavenger will exhibit both enhanced rates of reactivation 
and maximal recovery (10).  Based on this selection criteria, the combination of 
V146H/L363E results in a 48,700-fold increased in the rate of cyclosarin hydrolysis 
compared to wild type.  
 
3.5 pH profile of cyclosarin hydrolysis by V146H/L363E hCE1 mutant 
 The difference in free energy ("G = -RT ln(kreact Mutant 1/kreact Mutant 2)) between 
the rates of cyclosarin hydrolysis of L363E and V146H/L363E is approximately 1 kcal/mol, 
suggesting a weak bond is being formed between the His and Glu.  To explore how the 
V146H/L363E hCE1 mutants are interacting and determine whether a bond is being formed 
we measured the rates of spontaneous reactivation following cyclosarin inhibition from pH 4 
to 9.  The inflection points on the pH curve report the key ionizable states in cyclosarin 
hydrolysis.  To cover this range, 10 mM buffers of sodium phosphate (pH 3.37, pH 7.06, and 
pH 10.01), potassium formate (pH 4.13, 5.13), potassium phosphate (pH 6.2), TRIZMA (pH 
8.02), and sodium carbonate (pH 9.04) were used.  Samples of purified V146H/L363E hCE1 
mutant in 50 mM HEPES pH 7.4 were incubated with 10 nM cyclosarin for 5 minutes then 
confirmed for complete inhibition as previously described.  Excess agent was removed and 
samples were diluted 1:10 into appropriate buffers.  At various time points, aliquots were 
removed and assayed with 100 mM pNPB in 100 mM phosphate buffer pH 7.4 for CE 
activity.  Rates of spontaneous reactivation were determined by fitting data to equation 1. 
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 As shown in Figure 3.6, the pH profile exhibits only one pKa for the partnering E363 
and H146.  The inflection point near pH 6.2 is where H146 becomes deprotonated.  On a 
small peptide His has a pKa of 6.04 and Glu exhibits a pKa of 4.07 (11). These values are 
environment dependent and may change, especially if H146 and E363 are interacting.  
Unfortunately, below pH 4, both inhibited and uninhibited enzyme samples became 
denatured and no consistent catalytic activity was measured; therefore the deprotonation 
event of E363 could not be accessed. However the highest rates of cyclosarin hydrolysis are 
observed below pH 6.2, in the pH range where E363 is deprotonated and H146 is positively 
charged.  These observations support the conclusion that E363 is acting as the nucleophilic 
base for water activation and is stabilized by a charged H146 (Figure 3.7).  Once H146 
becomes deprotonated, E363 is destabilized, perhaps changing rotamers to sample the 
outside aqueous environment.     
 
3.6 Computational modeling of V146H/L363E hCE1 
 Based on these biochemical data E363 is most likely the nucleophilic base for water 
activation in cyclosarin reactivation and H146 stabilizes the position of this base.  Using the 
crystal structures of wild type hCE1 in complex with soman and cyclosarin we used 
computational protein design algorithms to model in the V146H/L363E mutations and 
examined their structural relationship.    
To prepare structures for computational design, a new residue type was created for 
S221 covalently inhibited by each of the OPs, GBX for sarin, GDX for soman, and GFX for 
cyclosarin. Following removal of all water molecules, saccharides, soman/cyclosarin, and 
extra monomers from the hCE1-soman and cyclosarin crystal structures (RCSB PDB 2HRQ, 
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3K9B (6, 7)), hydrogens were added into the protein structure using Molprobity (12). OP-
inhibited S221 hydrogens were added using Accelrys Discovery Studio Visualizer 2.5 
(Accelrys, San Diego, CA). Any strain or steric clashes in the structures were removed by 
performing 50 steps of conjugate gradient energy minimization.  
Residues with side chains pointing towards and within 5 Å of the organophosphorus, 
V146, or L363 residues (residues 89, 90, 93, 96, 97, 100, 101, 145, 146, 220, 222, 252, 254, 
255, 304, 318, 358, 359, 361, 363, 364, 388, 425, 426, and 468) were allowed to sample 
alternative conformations during the designs, but their identities were not modified. The 
crystallographic conformer at each designed position was also allowed. A standard 
backbone-dependent side chain rotamer library with expansions by one standard deviation 
about #1 and #2 was used (13). Prior to the modeling procedure, rotamer libraries for the 
various OPs (PS sarin, PR sarin, PRCR soman, PRCS soman, PSCR soman, PSCS soman, PR 
cyclosarin, and PS cyclosarin) were generated. These OP rotamer libraries introduced torsions 
in the phosphorus-alkoxy oxygen and alkoxy oxygen-carbon bonds of each free OP-bound 
serine residue, in 5° increments. The rotamers with conformational energies lower than a 
specified value (usually 0) were included in the OP rotamer library. Computational design 
was performed using the PHOENIX protein design software (X). The energy function used 
was based on the DREIDING force field and included a scaled van der Waals term, hydrogen 
bonding and electrostatic terms, and terms for implicit solvation and phi-psi propensities. 
Implicit solvation energies were evaluated using a model based on occluded volume. Amino 
acid phi-psi propensities were derived and applied following the method of Shortle (14). 
Sequence optimization was carried out with FASTER. 
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Figure 3.8A illustrates the energy minimized model of V146H/L363E hCE1 in 
complex with PR cyclosarin.  From this structure it is apparent that E363 and H146 form an 
ion pair, but not a salt bridge.  Salt bridges require that the side-chain charged group 
centroids are within a 4.0 Å distance and at least one pair of Asp/Glu side-chain carbonyl 
oxygen and Arg/Lys/His side-chain nitrogen atoms are also within this distance (15).  
According to the computational model V146H/L363E fulfills the second criteria, but not the 
first.  The distance between O"1 on the E363 anionic carboxylate head group and the cationic 
N"2 is 4 ± 1 Å at a 140o angle, but the distance between charged centroids is at least 5 ± 1 Å.  
Rather, H146 and E363 form a nitrogen-oxygen (N-O) bridge (16).  This stabilizing 
electrostatic interaction has been observed via NMR in multiple protein structures (16, 17).    
A conventional salt bridge would tie up E363, thereby eliminating the potential to 
activate a water molecule.  Through this N-O bridge, however, E363 stabilized for 
nucleophilic attack.  A water molecule can be positioned between E363 O"1 and the 
cyclosarin phosphonyl center, at a distance of 3.2 Å between each group and the water 
molecule (Figure 3.8B). The ability of this dyad to promote hydrolysis for cyclosarin more 
rapidly than soman and sarin is likely caused by the difference in O-alkoxy groups between 
the agents. The branched isopropyl and pinacolyl alkoxy groups in sarin and soman most 
likely exhibit greater degrees of rotational freedom than the spatially constrained cyclosarin 
cyclohexyl group, thereby limiting hydrolytic attack. 
 
3.7 Effect of nerve agent binding by V146H/L363E hCE1 mutant  
 Researchers have been trying to develop mutant esterases for the last 20 years that 
exhibit enhanced rates of reactivation towards OP nerve agents (5, 9).  The previously 
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described G117H/E197Q BChE mutant was the most successful cholinesterase variant thus 
far (9).  The deficiency with this mutant however, is that by enhancing the rate of 
reactivation, the ability of this enzyme to bind nerve agents is greatly diminished.  For 
example, the ability of G117H/E197Q BChE to bind soman is reduced over 1000-fold 
compared to WT, making this mutant an ineffective in vivo nerve agent scavenger.  The loss 
in binding affinity was attributed to G117H blocking OP entry into the active site (9). 
Using the stereogenic thiomethylated nerve analogs previously described in Chapter 
2.7 we determined the bimolecular rates of inhibition (ki) and dissociation constants (Kd) of 
V146H/L363E hCE1 for these compounds (7).  Samples of purified V146/L363E hCE1 at 
100 nM were inhibited at room temperature with increasing concentrations of stereogenic OP 
nerve agent analogs.  Aliquots of enzyme incubated with stereoisomer analogs of sarin (PR, 
PS), soman (PR, PS), and cyclosarin (PR, PS) were removed at various time points (up to 1 hr) 
and the level of active enzyme that remained was determined by comparing pNPB hydrolysis 
relative to an uninhibited sample.  These data, collected at 410 nm and 25 oC on a Pherastar 
microplate reader (BMG Labtech), were corrected for spontaneous pNPB hydrolysis and fit 
to equation 3 (18):   
       (3) 
where Kd was the dissociation constant, k2 the unimolecular phosphorylation rate constant, v 
the remaining percent enzyme activity, [IX] was the OP analog concentration, # was [S]/(KM 
+ [S]), in which [S] was the substrate concentration and KM was the Michaelis-Menton 
constant.  All experiments were performed in triplicate.  Data were analyzed in KaleidaGraph 
4 (Synergy Software, Reading, PA) to determine ki (ki = k2 / Kd) values.  
 
!t
!ln v
=
Kd
k2
* 1
[IX](1-")
+ 1
k2
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 As shown in Figure 3.9, the V146H/L363E hCE1 mutant did not drastically reduce 
the overall bimolecular rates of inhibition of this mutant for the nerve agent analogs.  Indeed, 
the dyad addition enhanced the enzymes affinity towards PS soman and cyclosarin isomers 
compared to wild type.  Table 3.5 details the effects of V146H/L363E on nerve agent analog 
binding.   The slight differences in ki between wild type and the dyad mutant are from the 
slower rates of phosphonylation (k2) in the novel enzyme (7), which could be associated with 
active site changes induced by the mutants.  These slower rates however are balanced by the 
enhanced binding affinity (Kd) of V146H/L363E for each analog.  The mutant enzyme 
drastically reduced the previous absolute PR stereoprefence, especially for the cyclosarin 
analog.  The PR/PS binding ratio was reduced from 2900 in the wild type enzyme to only 45 
for the mutant (7).  Overall these data confirm that unlike the G117H/E197Q BChE, the tight 
binding affinity of carboxylesterases for OP nerve agents was not diminished in the 
V146H/L363 hCE1 mutant. 
 
3.8 An Efficient Enzyme 
 Through the V146H/L363E dyad addition we increased the Adjusted rate of 
reactivation for cyclosarin 48,000-fold over wild type while still maintaining nM binding 
affinity.  Combining these two terms (kcat/Km) describes an enzyme’s efficiency (19).  
Because it is believed reactivation is the slowest step in the enzymatic pathway, we 
approximate that kreact $ kcat.  Additionally, the Kd towards the thiomethylated cyclosarin 
analog is representative of the Kd for bona fide agents (7, 20).  By combining these terms we 
arrive at a kcat/Km of V146H/L363E hCE1 for cyclosarin of 1.8 x 103 M-1 s-1, four orders of 
magnitude more efficient than the soman hydrolyzing G117H/E197Q BChE (9).  When 
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compared to other rational protein designs towards hemisubstrates, or enzymes that bind a 
given substrate but have no catalytic activity on that substrate, we have created the current 
most efficient enzyme described to date (Table 3.6).  Other designed enzymes include 
peptidase activity into cyclophilin through a Ser-His-Asp catalytic triad addition, 
phosphatase activity in phospho- (serine/threonine/tyrosine) binding proteins by adding a 
catalytic cysteine, thioester hydrolysis in glutathione transferase A1-1 with a nucleophilic His 
addition, and oxaloacetate decarboxylesterase into 4-oxalocrotonate tautomerase by 
generating a N-terminal tertiary amine to induce Schiff base formation (21-24).  In terms of 
all designed enzymes, rationally, computationally, or evolutionarily, the most efficient 
enzyme, so far, resulted from the combination of de novo protein design and directed 
evolution (25).  The Kemp elimination pathway designed into a TIM barrel exhibits a kcat/Km 
of 2.6 x 103 M-1 s-1, approximately 1.5x more efficient than V146H/L363 hCE1.  
 
3.9 Conclusion 
 Despite the dramatic increase in the rate of spontaneous reactivation of 
V146H/L363E hCE1 towards cyclosarin, this mutant enzyme is still too slow to be used as a 
catalytic bioscavenger.  The ideal catalytic bioscavenger candidate must bind nerve agents on 
the nM scale and exhibit reactivation rate constants on the order of 1 min-1, we are still two-
orders of magnitude away from that benchmark (personal communication with Dr. Douglas 
Cerasoli, USAMRICD).  The rate-limiting step in the reaction pathway may now be product 
release, so we are in the process of making mutations that open up the active site pocket, 
potentially further enhancing the rate of nerve agent hydrolysis.  Indeed, as shown in 
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Chapter 5, a loop truncation to open up the active site pocket greatly enhanced that rate of 
oxime induced sarin hydrolysis compared to wild type hCE1.   
 
3.10 Figures and Tables  
Figures and tables are listed in the same order they appear in the text of chapter 3. 
Figure 3.1 Ester hydrolysis by hCE1 
Figure 3.2 Mechanism of nerve agent inhibition in hCE1 
Figure 3.3 Active site of hCE1 covalently inhibited by soman 
Table 3.1 Primers used for mutant incorporation in hCE1 
Figure 3.4 Rates of spontaneous reactivation for V146H/L363E hCE1 mutant 
Figure 3.5 Rates of spontaneous reactivation for control mutants   
Table 3.2 Reactivation kinetics by hCE1 mutants after sarin inhibition 
Table 3.3 Reactivation kinetics by hCE1 mutants after soman inhibition 
Table 3.4 Reactivation kinetics by hCE1 mutants after cyclosarin inhibition 
Figure 3.6 pH profile for spontaneous cyclosarin hydrolysis by V146H/L363E hCE1 
Figure 3.7 pH based mechanism for cyclosarin hydrolysis by V146H/L363E hCE1 
Figure 3.8 Energy minimized structures of V146H/L363E hCE1 mutant with cyclosarin 
Figure 3.9 Bimolecular rates of inhibition of V146H/L363E hCE1 with stereogenic nerve 
agent analogs 
Table 3.5 Inhibition constants of V146H/L363E hCE1 with nerve agent analogs 
Table 3.6 Enzyme efficiency of rationally designed enzymes 
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Figure 3.1  Ester hydrolysis by hCE1.  H468 deprotonates S221, leading to a nucleophilic 
attack of an ester substrate.  Upon collapse of the tetrahedral intermediate, an alcohol 
dissociates, deprotonating H468, resulting in an acyl enzyme intermediate.  H468 then 
activates a water molecule for nucleophilic attack on the acyl carbonyl center, forming a 
second transition state.  Finally, the newly formed carboxylic acid dissociates from S221, 
regenerating the enzyme for another round of catalysis.  
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Figure 3.2 Catalytic complication of nerve agent inhibition in esterases.  After resolve of 
the initial pentahedral transition state, the departing fluoride has a much lower pKa than the 
traditional ester alcohol, likely leaving H468 protonated.  Adding a base (His or Glu) into the 
active site may enable water activation and reactivation of S221. 
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Figure 3.3 Active site of human carboxylesterase 1 covalently inhibited with soman.  
The active site residues S221, H468, and E354 (yellow), are surrounded by hydrophobic  
residues (grey surface), including L97 (grey), V146, and L363 (light blue).     
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Table 3.1 Primers used for mutant incorporation in hCE1. 
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Figure 3.4 Rates of spontaneous reactivation for V146H/L363E hCE1 mutant.  
Reactivation in the presence of sarin (!), soman (") and cyclosarin (#).  Sarin is hydrolyzed 
4.5x faster than wild type, soman ~100x faster, and cyclosarin >1000x faster.  For 
comparison, reactivation of wild type enzyme is shown in grey (7). N=3, S.E. 
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Figure 3.5 Rates of spontaneous reactivation for control mutants.  V146H and L363Q 
recover following sarin and soman inhibition, but cannot hydrolyze cyclosarin.  L363E can 
spontaneously reactivate following cyclosarin inhibition, but slowly recovers after sarin and 
soman exposure.  V146Q/L363E may assist in stabilizing the carboxylate base, but the 
synergistic combination of V146H/L363E exhibits broad-spectrum nerve agent hydrolysis. 
N=3, S.E.     
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Table 3.2 Reactivation kinetics by hCE1 mutants following sarin inhibition. pH 7.4, 
25oC, N=3, S.E. Adjusted kreact = (kreact x Amax) / 100, Fold enhancement = Adjusted kreact Mut 
/ Adjusted kreact WT 
N.R. is no-reactivation (<1 x 10-5 min-1), a(7) 
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Table 3.3 Reactivation kinetics by hCE1 mutants following soman inhibition. pH 7.4, 
25oC, N=3, S.E. Adjusted kreact = (kreact x Amax) / 100, Fold enhancement = Adjusted kreact Mut 
/ Adjusted kreact WT 
N.R. is no-reactivation (< 1 x 10-5 min-1), a(7) 
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Table 3.4 Reactivation kinetics by hCE1 mutants following cyclosarin inhibition. pH 
7.4, 25oC, N=3, S.E. Adjusted kreact = (kreact x Amax) / 100, Fold enhancement = Adjusted kreact 
Mut / Adjusted kreact WT 
N.R. is no-reactivation (< 1 x 10-5 min-1), a(7) 
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Figure 3.6 pH profile for spontaneous cyclosarin hydrolysis by V146H/L363E hCE1.  
The reactivation profile of V146H/L363E hCE1 against cyclosarin from pH 4 to 10 has a 
sharp inflection point at pH 6.2.  This corresponds with the pKa of H146.  The pKa of E363 
is below pH 4 and therefore not accessible by this experiment.  These data show that the most 
active form of the mutant enzyme for cyclosarin hydrolysis is when E363 is deprotonated and 
H146 is charged.  H146 hCE1 exhibited no reactivation following cyclosarin inhibition.  
N=3, S.E.   
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Figure 3.7 Energy minimized structures of V146H/L363E hCE1 mutant with cyclosarin.  
A) The mutated E363 and H146 sit above the active site pocket.  E363 O"1 forms an N-O 
bridge (4 Å) with N"2 of H146 and is 4.4 Å away from the cyclosarin cyclohexyl ring.  B) 
View rotated by ~90o,  E363 is 6.6 Å away from the phosphate center, a modeled water can 
fit 3.2 Å away from the key atoms.  Atomic surface shown.   
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Figure 3.8.  Bimolecular rate constants of inhibition for V146H/L363E with 
thiomethylated OP nerve agent analogs.  The PR/PS ratios for V146H/L363E with soman 
and cyclosarin analogs are greatly reduced compared to WT enzyme, suggesting that these 
mutations have enhanced PS binding affinity a(7).   
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Table 3.5 Inhibition constants of V146H/L363E hCE1 with nerve agent analogs.  The 
bimolecular rates of inhibition (ki) are similar in magnitude to WT a(7).  V146H/L363E hCE1 
exhibits smaller dissociation constants (Kd) than WT, but slightly slower rates of 
phosphonylation (k2).     
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Table 3.6 Enzymatic efficiency of rational designed enzymes.  The designed 
V146H/L363E hCE1 mutant is the most efficient rationally designed enzyme towards a 
hemisubstrate.  The above listed rationally designed enzymes are other examples where the 
natural protein bound the desired substrate, but was not capable of performing the designed 
activity. a(9), b(24), c(26) 
 
 
 
 
 
 
 
 
 
 83 
 
REFERENCES 
1. Aharoni, A., Gaidukov, L., Khersonsky, O., Mc, Q. G. S., Roodveldt, C., and Tawfik, 
D. S. (2005) The 'evolvability' of promiscuous protein functions, Nat Genet 37, 73-
76. 
 
2. Redinbo, M. R., and Potter, P. M. (2005) Mammalian carboxylesterases: from drug 
targets to protein therapeutics, Drug Discov Today 10, 313-325. 
 
3. Shen, T., Tai, K., Henchman, R. H., and McCammon, J. A. (2002) Molecular 
dynamics of acetylcholinesterase, Acc Chem Res 35, 332-340. 
 
4. Lenz, D. E., Broomfield, C. A., Yeung, D., Masson, P., Maxwell, D. M., and 
Cerasoli, D. M. (2008) Nerve Agent Bioscavengers: Progress in Development of a 
New Mode of Protection against Organophosphorus Exposure, in Chemical Warfare 
Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics (Romano Jr., J. A., 
Lukey, B. J., and Salem, H., Eds.) 2nd ed., CRC Press, Boca Raton, FL. 
 
5. Millard, C. B., Lockridge, O., and Broomfield, C. A. (1995) Design and expression of 
organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase, 
Biochemistry 34, 15925-15933. 
 
6. Fleming, C. D., Edwards, C. C., Kirby, S. D., Maxwell, D. M., Potter, P. M., Cerasoli, 
D. M., and Redinbo, M. R. (2007) Crystal structures of human carboxylesterase 1 in 
covalent complexes with the chemical warfare agents soman and tabun, Biochemistry 
46, 5063-5071. 
 
7. Hemmert, A., Otto, M. F., Wierdl, M., Edwards, C. C., Fleming, C. D., MacDonald, 
M., Cashman, J. R., Potter, P. M., Cerasoli, D. M., and Redinbo, M. R. (2010) Human 
Carboxylesterase 1 Stereoselectively Binds the Nerve Agent Cyclosarin and 
Spontaneously Hydrolyzes the Nerve Agent Sarin, Molecular Pharmacology IN 
PRESS. 
 
8. Denu, J. M., and Dixon, J. E. (1998) Protein tyrosine phosphatases: mechanisms of 
catalysis and regulation, Curr Opin Chem Biol 2, 633-641. 
 
9. Millard, C. B., Lockridge, O., and Broomfield, C. A. (1998) Organophosphorus acid 
anhydride hydrolase activity in human butyrylcholinesterase: synergy results in a 
somanase, Biochemistry 37, 237-247. 
 
10. Lenz, D. E., Yeung, D., Smith, J. R., Sweeney, R. E., Lumley, L. A., and Cerasoli, D. 
M. (2007) Stoichiometric and catalytic scavengers as protection against nerve agent 
toxicity: a mini review, Toxicology 233, 31-39. 
 
 84 
11. Voet, D., Voet, J. G., and Pratt, C. W. (2002) Fundamentals of Biochemistry upgrade, 
Upgrade Edition ed., John Wiley & Sons, Inc., New York. 
 
12. Chen, V. B., Arendall, W. B., 3rd, Headd, J. J., Keedy, D. A., Immormino, R. M., 
Kapral, G. J., Murray, L. W., Richardson, J. S., and Richardson, D. C. (2009) 
MolProbity: all-atom structure validation for macromolecular crystallography, Acta 
Crystallogr D Biol Crystallogr 66, 12-21. 
 
13. Dunbrack, R. L., Jr., and Cohen, F. E. (1997) Bayesian statistical analysis of protein 
side-chain rotamer preferences, Protein Sci 6, 1661-1681. 
 
14. Shortle, D. (2003) Propensities, probabilities, and the Boltzmann hypothesis, Protein 
Sci 12, 1298-1302. 
 
15. Kumar, S., and Nussinov, R. (1999) Salt bridge stability in monomeric proteins, J 
Mol Biol 293, 1241-1255. 
 
16. Kumar, S., and Nussinov, R. (2002) Relationship between ion pair geometries and 
electrostatic strengths in proteins, Biophys J 83, 1595-1612. 
 
17. Kumar, S., and Nussinov, R. (2002) Close-range electrostatic interactions in proteins, 
Chembiochem 3, 604-617. 
 
18. Aurbek, N., Thiermann, H., Szinicz, L., Eyer, P., and Worek, F. (2006) Analysis of 
inhibition, reactivation and aging kinetics of highly toxic organophosphorus 
compounds with human and pig acetylcholinesterase, Toxicology 224, 91-99. 
 
19. Wolfenden, R. (2006) Degrees of difficulty of water-consuming reactions in the 
absence of enzymes, Chem Rev 106, 3379-3396. 
 
20. Forsberg, A., and Puu, G. (1984) Kinetics for the inhibition of acetylcholinesterase 
from the electric eel by some organophosphates and carbamates, Eur J Biochem 140, 
153-156. 
 
21. Brik, A., D'Souza, L. J., Keinan, E., Grynszpan, F., and Dawson, P. E. (2002) 
Mutants of 4-oxalocrotonate tautomerase catalyze the decarboxylation of oxaloacetate 
through an imine mechanism, Chembiochem 3, 845-851. 
 
22. Quemeneur, E., Moutiez, M., Charbonnier, J. B., and Menez, A. (1998) Engineering 
cyclophilin into a proline-specific endopeptidase, Nature 391, 301-304. 
 
23. Wishart, M. J., Denu, J. M., Williams, J. A., and Dixon, J. E. (1995) A single 
mutation converts a novel phosphotyrosine binding domain into a dual-specificity 
phosphatase, J Biol Chem 270, 26782-26785. 
 
 85 
24. Hederos, S., Broo, K. S., Jakobsson, E., Kleywegt, G. J., Mannervik, B., and Baltzer, 
L. (2004) Incorporation of a single His residue by rational design enables thiol-ester 
hydrolysis by human glutathione transferase A1-1, Proc Natl Acad Sci U S A 101, 
13163-13167. 
 
25. Khersonsky, O., Rothlisberger, D., Dym, O., Albeck, S., Jackson, C. J., Baker, D., 
and Tawfik, D. S. (2009) Evolutionary Optimization of Computationally Designed 
Enzymes: Kemp Eliminases of the KE07 Series, J Mol Biol 28, 28. 
 
26. Toscano, M. D., Woycechowsky, K. J., and Hilvert, D. (2007) Minimalist active-site 
redesign: teaching old enzymes new tricks, Angew Chem Int Ed Engl 46, 3212-3236. 
 
 
!!!!!
Chapter 4. Novel Enzyme-Based Nerve Agent Identification 
Device 
 
4.1 Nerve Agent Detection 
 Military warfighters and HAZMAT emergency first responders are trained to 
recognize the signs and symptoms of nerve agent exposure.  These acetylcholine based 
muscarinic and nicotinic effects are best described by the nemonic SLUDGE (salivation, 
lacrimation, urination, defecation, gastrointestinal pains, and emesis).  The onset and 
intensity of these conditions, determined by route and length of exposure, can be partially 
mitigated by post-exposure therapies. As described in Chapter 1.4, current treatments for OP 
poisoning include injections of atropine and a critical strong-nucleophile oxime (1).  One 
deficiency of this therapy however is that there is no broad-spectrum oxime.  For example 2-
PAM can reactivate AChE inhibited by sarin or the V-agents, while another oxime, 
Obidoxime, is only effective against sarin, tabun, and the V-agents (2).  Between the four 
oximes currently suitable for therapeutic use, exposure to G- or V-agents can all be 
effectively treated (Figure 4.1) (2). Thus, to utilize the already available oximes, it is 
essential to accurately and quickly identify the specific nerve agent(s) present in an attack. 
 The current point nerve agent identification technologies employed by the U.S. 
military and HAZMAT first-responders include electronic and colorimetric detectors (3-5).  
Electronic devices, such as the JCAD produced by Smiths Detection, utilizes Differential Ion 
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Mobility Spectroscopy (DMS) to detect and identify chemical agent vapors.  These devices 
are effective at identifying low levels of toxins, but are costly, bulky, require external power, 
and constant calibration (4).  Colorimetric detectors such as the M256A1 kit, M8/M9 paper, 
or Agentase CAD-kit are no-power methods to detect chemical agents, but cannot distinguish 
between different nerve agents and are known to suffer from a high rates of false positives 
(3).  The read-out on these colorimetric devices only discriminates between G- and V-agents, 
thereby significantly limiting administration of the best oxime antidote.  An ideal device 
would provide robust, rapid, no power and cost-effective identification of specific nerve 
agents. 
 
4.2 hCE1 Mutants for Nerve Agent Detection 
 Despite the impressive increases in spontaneous rates of reactivation with the 
designed hCE1 mutants, these enzymes are still too slow to be utilized as effective 
bioscavengers.  Indeed, even with the 48,700-fold increase in cyclosarin hydrolysis, the 
V146H/L363E hCE1 mutant would still only behave as a stoichiometric bioscavenger, 
regenerating every hour.  Additionally, because of the intrinsic active site architecture, these 
hCE1 mutants still exhibit a strong preference for the less toxic stereoisomers of most G-
agents.  These two factors may limit the prophylactic potential of designed hCE1 enzymes, 
but these mutant proteins are ideally positioned to aid in nerve agent detection and 
identification.   
During the mutant design process it was observed that certain mutants exhibited 
unique hydrolytic specificity towards each agent (Figure 4.2).  For example V146H/L363Q 
hCE1 only reactivates following sarin inhibition, with a half-time of reactivation of  ~2 
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hours, while V146H/L363E hCE1 reactivates following cyclosarin inhibition with a half-time 
of approximately 1 hr.  Unlike the necessity of a catalytic bioscavenger to return to maximal 
activity after nerve agent inhibition, enzymes used for detection and identification may only 
partially reactivate since the rate of reactivation is the most important characteristic.  
Additionally, in some mutants this rate can be further enhanced through oxime assistance.  
 
4.3 Ability of hCE1 Mutants to Identify Nerve Agent Analogs 
 Through a secondary colorimetric substrate assay following nerve agent inhibition, 
we tested the ability of the novel hCE1 mutant L97K to detect and identify nerve agent 
analogs. This single mutation exhibits spontaneous reactivation against bona fide soman, 
with a half time of reactivation of 73 minutes, and can also recover following sarin 
inhibition, (t1/2 ~ 6 hours).  L97K does not reactivate following racemic cyclosarin or tabun 
inhibition.    Using the thiomethylated nerve agent analogs, 50 !L of COS cells containing 
wild type or the hCE1 L97K mutant were exposed to 1 mM sarin, soman, or cyclosarin 
analogs.  Following inhibition for 10 minutes, aliquots were diluted 1:10 into 10 mM para-
nitrophenol butyrate (pNPB) at pH 7.4.  hCE1 cleaves this ester substrate to release o-
nitrophenol, a small molecule that absorbs light in the visible spectrum.  Analytically, this 
hydrolysis event is measured through absorbance at 410 nm, while qualitatively the sample 
will turn yellow.  Differences in color change could be observed 30 seconds after 
colorimetric substrate addition for soman and sarin analogs (Figure 4.3).  This rapid color 
change may either be attributed to the L97K mutant hydrolyzing sarin and soman analogs, or 
the mutant was poorly inhibited compared to wild type enzyme.  
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4.4 Detection Limits of hCE1 Mutants 
 One challenge with current protein-based nerve agent detection devices is that the 
enzyme catalyzed colorimetric readout can be swamped out by excess OP sample. With the 
above-mentioned thiomethylated nerve agent analogs we determined the detection range of 
the V146H/L363Q hCE1 mutant with sarin, soman, and cyclosarin analogs.  Fifty !L of COS 
enzyme containing sample was inhibited with nerve agent analog concentrations ranging 
from 10 !M to 4 mM for 10 minutes, prior to 10 mM pNPB substrate addition.   These 
analogs have previously been shown to form identical adducts to OP nerve agents (6) but as 
previously mentioned, have 1,000-fold reduced potency stemming from the slower rates of 
phosphonylation (k2) (7).  As shown in Figure 4.4 the V146H/L363Q mutant optimally 
differentiates between nerve agent analogs from 10 !M to 1 mM, suggesting that bona fide 
agents should be detected between 10 nM to 1 !M, below or near the nerve agent LD50 (800 
nM) (8).    
 
4.5 Mutant Incorporation in Nerve Agent Identifying Device 
We are currently working on entrapping these mutant enzymes for a small, hand-held 
device that requires no power to detect and identify various agents.  A spatially separated 
array should enable the identification of all known nerve agents.  As illustrated in Figure 4.5, 
each OP will have a unique visual readout.  V146H/L363Q will reactivate sarin, L97K will 
identify soman, and V146H/L363E hydrolyzes cyclosarin.  AChE will also be incorporated 
into the device to enable VX and tabun detection.  As described in Chapter 2.5, hCE1 does 
not react with VX; therefore each of the hCE1 mutants will remain available for substrate 
hydrolysis, while AChE will be inhibited.  Lastly, all the enzymes are inhibited by tabun, but 
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inclusion of the oxime obidoxime into the buffer solution will rapidly reactivate AChE.  As 
previously mentioned hCE1 does not interact with this charged oxime.   
 
4.6 Summary 
 With this technology in mind, we recently incorporated Identizyme Defense 
Technologies, and applied for a Department of Defense Phase I SBIR grant to further fund 
the development of this device.  The storage and operational conditions, effects of field 
interferents on detection, and detection/identification range against bona fide agents still need 
to be tested.  We anticipate that this type of device can replace the antiquated M256A1 
chemical agent detection kit currently used by the U.S. military. The University of North 
Carolina at Chapel Hill has filed a provisional U.S. patent for these enzymes and their use for 
nerve agent and pesticide detection (USSN: 61/267,591)  
 
4.7 Figures and Tables 
Figures are listed in the same order they appear in the text of chapter 4. 
Figure 4.1 Comparison of oxime efficacy for acetylcholinesterase reactivation 
Figure 4.2 Spontaneous rates of reactivation of hCE1 mutants towards G-agents 
Figure 4.3 Nerve agent analog identification by hCE1 mutant 
Figure 4.4 Detection and Identification range of hCE1 with nerve agent analogs 
Figure 4.5 Enzyme-based nerve agent identifying device 
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Figure 4.1 Comparison of oxime efficacy for acetylcholinesterase reactivation.  Current 
administered oximes for nerve agent exposure include pralidoxime and obidoxime.  As 
illustrated however, these oximes are ineffective against soman or cyclosarin.  Additionally, 
there is no broad-spectrum oxime (2).  Identification of a given agent could facilitate 
administration of the most effective antidote.     
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Figure 4.2 Spontaneous rates of reactivation of hCE1 mutants towards G-agents.  The 
mutants V146H/L363Q, L97K, and V146H/L363E all exhibit unique rates of reactivation 
against each G-agent.  V146H/L363Q reactivates after sarin inhibition, L97K rapidly 
recovers after soman exposure, and V146H/L363E can hydrolyze cyclosarin.  These 
mutations are shown modeled into the hCE1 active site.  
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Figure 4.3 Nerve agent analog identification by hCE1 mutant.  Following a 10 minute 
incubation with either sarin or soman nerve agent analogs, there is a clear visual difference 
wild type and L97K hCE1 to hydrolyze pNPB.  This scan was taken 30 seconds after pNPB 
addition.  No inhibitor was present in (-).  Soman identification by L97K may either be from 
OP analog hydrolysis or lack of mutant inhibition in the 10 minute exposure.     
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 Figure 4.4 Detection and identification range of hCE1 with nerve agent analogs.  The 
hCE1 mutant V146H/L363Q can detect and differentiate between nerve analogs most 
effectively at 100 !M.  Due to the thiomethyl leaving group, these analogs are ~1000x less 
potent inhibitors of esterases (7), suggesting that the hCE1 mutant will be able to identify 
nerve agents below one LD50 (800 nM (8)).  
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 Figure 4.5 Enzyme-based nerve agent identifying device.  By spatially separating the 
various hCE1 mutants along with acetylcholinesterase, we could generate a no-power device 
that may rapidly detect and identify all known OP nerve agents.  Such a device could enable 
efficient identification and antidote administration. 
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Chapter 5.  Structural and Biochemical Differences of 
Mammalian Carboxylesterases  
 
5.1 Mammalian Carboxylesterases 
Human carboxylesterase 1 (hCE1) is a primary hydrolytic drug-metabolizing 
enzyme found in the liver (1).  This serine hydrolase, however, is only one of many 
mammalian carboxylesterases.  Even though these promiscuous enzymes bind a wide 
range of xenobiotics and catalyze hydrolytic and transesterification reactions, they also 
exhibit unique catalytic rates for these various compounds (2).  For example, human 
intestinal carboxylesterase (hiCE) hydrolyzes the ester prodrug, Irinotecan (CPT-11), 90 
times more efficiently than hCE1 (3).  This chemotherapeutic is cleaved to form 7-ethyl-
10-hydroxycamptothecin (SN-38), a potent topoisomerase inhibitor (4).  Additionally, the 
rat serum carboxylesterase (rsCE) exhibits 15-fold faster rates of spontaneous 
reactivation against organophosphate (OP) nerve agents than hCE1 (5).   
 As we and others have shown, these enzymes are robust to mutations, many of 
which can enhance catalytic activity (3, 6). Indeed, as presented in Chapter 3, two 
mutations in hCE1 increased the rate of reactivation after OP inhibition above that 
measured with rsCE.  Also, by altering 7 amino acids in hCE1, researchers were able to 
enhance CPT-11 hydrolysis in this enzyme to hiCE levels (3).  To understand the 
structural constraints that lead to differing CE activities we performed multiple sequence 
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alignments across a range of human and rodent carboxylesterases to identify functionally 
essential differences.   
 
5.2 Liver carboxylesterase acyl-loop identification 
All mammalian carboxylesterases belong to the !/" serine hydrolase superfamily, 
and share the conserved beta-sheet backbone surrounded by helices and loops (7).  As 
shown in Figure 5.1, sequence alignments of multiple mammal carboxylesterase, both 
from liver and serum, reveal three diverging sequence clusters (GenBank accession 
numbers hCE1 AAA35649, rabbit liver CE AAC3925, rat liver CE CAA46391, mouse 
liver CE CAA73388, mouse serum CE AAA63297, rsCE CAA55241, and hiCE 
CAA70831).  These are the 18-residues N-terminal signal peptide, a 15-residue section in 
the middle of the protein alignment, and the 4-residue ER retention sequence.  The initial 
and latter sequences determine cellular localization and retention and will be different for 
each protein (7, 8), but the 15-residue difference between the liver and serum/intestinal 
CEs is unique.   It is worth noting that human do not express a serum carboxylesterase, 
which can be attributed to the conserved KDEL like C-retention sequence (HIEL in 
hCE1, HTEL in hiCE) (8).  Both the rat and mouse serum CEs have non-retaining 
sequences (TEHK) (9).  
As shown in the hCE1-soman crystal structure (RSCB PDB 2HRQ), these 15 
residues correspond to a long, flexible loop that covers the top of the active site (Figure 
5.2) (10).  This loop has been termed the acyl-loop, based on interactions with acyl-
enzyme intermediates in AChE and BChE (10).  In these cholinesterases the acyl-loop 
dips into the active site pocket, while in hCE1 it covers the top, like a lid on a can.  The 
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only existing mammalian carboxylesterase crystal structures are for hCE1 and rCE, both 
of which contain these 15 residues, although it was disordered in rCE. This region 
typically exhibits high crystallographic temperature factors, and was also completely 
disordered in the hCE1-cyclosarin model (6, 11).   To understand the structural 
significance of this loop we utilized InsightII (Acclerys, San Diego) and hCE1 as a 
template, and constructed a  homology model of rsCE and hiCE, both of which do not 
contain the acyl-loop.  These enzymes share 68% and 42% sequence homology with 
hCE1, respectively.  As shown in Figure 5.3, without the acyl loop, the active site 
opening of rsCE is significantly larger than hCE1.  Based on this observation, we 
hypothesized that this enhanced entrance might facilitate the unique catalytic activities 
observed in non-loop containing enzymes compared to hCE1.  
 
5.3 hCE1 acyl-loop deletion 
To test this hypothesis, we truncated the acyl loop in wild type hCE1 and 
determined the effect this deletion had on enzymatic activity. Initially, by overlaying the 
hCE1 and rsCE models we identified appropriate deletion sites that would not affect 
additional secondary structure.  As listed in Table 5.1, custom primers were designed that 
omitted residues 301-313 and mutated residues 314-320 to match the shorter rsCE linker.  
Two batches of PCR were performed, the first consisted of separate reactions of pUC9 
hCE1 template plasmid replicating with either the sense or antisense primers only.  The 
second batch combined equal volumes of each reaction to complete deletion and mutant 
incorporation.  After PCR, template strands were digested with Dpn1 for 1 hr. at 37oC 
and then transformed into DH5! cells.  As described in Chapter 2.4 successful mutants 
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were sequence verified, cloned into the pCI-neo mammalian expression vector, and 
expressed in COS cells (3).  This loop deletion and linker mutation was coined the loop 
deletion (LD) mutant.  Based on the rsCE homology model, additional mutations were 
engineered into hCE1 LD, to make the hCE1 active site more “rat serum-like”.  As 
shown in Table 5.1, these are identified as LD1 through LD4.  
 
5.4 Enzymatic Changes in hCE1 LD Mutant. 
   Table 5.2 reports the effect of each LD mutant on CE activity, SN-38 
production, spontaneous rate of sarin hydrolysis, and rate of oxime-assisted sarin 
hydrolysis compares to wild type protein.  Carboxylesterase activity was determined by 
measuring the rate of o-nitrophenol production per mg enzyme at 410 nm following 
addition of 3 mM o-nitrophenol acetate (oNPA), a conventional substrate. To correct for 
differences in CE expression within transfected COS cells, the enzyme activity values 
were corrected for the level of immunoreactive CE protein as determined from western 
blot analyses (3).  Wild type hCE1 produces approximately 2520 ± 60 nM/min/mg.  The 
LD hCE1 mutant reduced this rate in half and further mutations within the active site 
pocket reduced oNPA hydrolysis to about 3% the wild type activity.  The most dramatic 
decrease came after the addition of L388N.  This mutation is in the active site “side-
door”, a secondary opening to the active site that has been implicated in cocaine 
transesterification with ethanol or product release following CPT-11 hydrolysis (11, 12).  
It is unknown what role this side-door plays in rsCE.  Since protein expression levels 
were normalized a reduction in carboxylesterase activity may suggest a decrease in 
promiscuous activity towards this substrate.   
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 Conversion of CPT-11 into SN-38 was monitored by incubating cell extracts with 
5 mM CPT-11 for 1 h in 50 mM HEPES (pH 7.4) at 37oC. An equal volume of acidified 
methanol was added to terminate the reactions and particulate matter was removed by 
centrifugation at 100,000 g for 5 min at 4oC. Concentrations of both drugs in the 
supernatant were then determined by high-performance liquid chromatography (3).  As 
previously mentioned, wild type hCE1 poorly hydrolyzes CPT-11, with an average 
activity of 0.36 ± 0.017 nM/min/mg protein.  hiCE, which is missing the acyl-loop, 
hydrolyzes CPT-11 approximately 90 times more efficiently (3).  The rates of hydrolysis 
between these two enzymes aren’t drastically different (1.49 nmol/min/mg vs. 0.36), but 
hiCE binds CPT-11 approximately 25 times tighter than hCE1 (3.35 !M vs. 82.8 !M) 
(3).  As shown in Table 5.2, the loop deletion mutants enhanced the rate of SN-38 
production up to 62-fold over wild type enzyme.  This large increase matches a rate 
enhancement achieved by other researchers in mutating the hCE1 active site to be more 
“rabbit-liver” like (hCE1m6) (3).     
 As shown in Figure 5.4, two structural features are consistent among the three 
CPT-11 hydrolyzing enzymes (hiCE, hCE1m6, and hCE1 LD4).  These enzymes all 
contain an open active-site entrance, either through absence of the acyl-loop or 
engineered disorder, and they all exhibit a patch of polar residues near the active sites 
side door.  Irinotecan is a large, multi-ringed, substrate covalently modifies with a 
dipiperdine group to enhance solubility (4).  In order for a carboxylesterase to cleave this 
substrate, the solubilizing group would sit deep into the active site pocket, while the 
larger SN-38 moiety resides where the acyl-loop would be positioned.  By removing the 
acyl-loop from hCE1, this space is now available to accommodate the large substrate.  In 
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the hCE1m6 mutant, a helix adjacent to the acyl-loop was mutated to mirror a disordered 
loop in rCE.  The second structural feature is a patch of polar resides near the active-site 
side door.  In hiCE there is an arginine, hCE1m6 contains a glutamine, and hCE1 LD4 
has two asparagines.  In hCE1m6 and hCE1 LD4 is was only after the addition of these 
polar residues that maximum CPT-11 activity was achieved (3).  These residues may be 
important to support the SN-38 lactone on the critical E ring, which would be positioned 
in that region.  To support these ideas, additional measurements such as binding constant 
determination are required and underway. 
 Rates of reactivation following nerve agent inhibition were carried out as 
described in Chapters 2.8 and 2.9.  Briefly, COS cell lysates expressing wild type or 
mutant hCE1 were incubated with ~1000-fold molar excess of racemic sarin.  After 
confirmation of complete inhibition, excess agent was removed and samples were diluted 
into solutions with and without 1 mM DAM prior to activity determination relative to an 
uninhibited sample (6, 10).  Removal of the acyl-loop and mutation of the hCE1 active 
site to resemble the rsCE did not dramatically increase the rates of spontaneous 
reactivation towards sarin.  rsCE spontaneously reactivates after sarin inhibition 13x 
faster than hCE1 (5).  These modifications did however increase the rate of oxime-
assisted reactivation 15x after sarin inhibition in hCE1 LD4 compared to wild type (6).  
The half time for reactivation of this mutant is now ~2 minutes, within the benchmark 
range for a catalytic bioscavenger (13).  Removing the acyl-loop may have enhanced 
DAM binding by removing the a barrier into the active site.  This will be confirmed by 
determining the Michaelis-Menton kinetics of this mutant with DAM.  Additionally, we 
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are combining the V146H/L363E mutant with LD4 to potentially generate a mutant that 
eliminates any kinetic slowdown caused by product release.   
 
5.5 Summary 
 Overall these initial data suggest that the 15-residue acyl-loop lid that caps the 
hCE1 active plays an important role in substrate access and binding.  Additional 
measurements need to be made to determine the kinetics effects of the loop deletion.  We 
are the first to observe this 15-amino acid difference in esterases and are excited to finish 
the experiments required to build a complete story. 
 
5.6 Figures and Tables 
Figures are listed in the same order they appear in the text of chapter 5. 
Figure 5.1 Multiple sequence alignment of mammalian carboxylesterases 
Figure 5.2 Acyl-loop in wild type hCE1 
Figure 5.3 Homology model of rsCE 
Table 5.1 Custom designed primers for hCE1 LD mutants 
Table 5.2 Effects of LD mutations on various CE substrates 
Figure 5.4 Homology model of hCE1 LD4 with CPT-11 
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Figure 5.1 Multiple sequence alignment of mammalian carboxylesterases.  From this 
sequence alignment of human, rabbit, rat, mouse carboxylesterases, three divergent 
regions can be identified (red boxes). The 18-residue N-terminal leader sequence directs 
newly synthesized protein to the endoplasmic reticulum (ER).  Additionally the C-
terminal 4-residue retention sequence either aids in retention of CE within the ER, or 
allows the enzyme to enter the serum.  The 15-amino acid patch around residue 320 is the 
acyl-loop.  These CEs all share high homology in the catalytic machinery (green boxes). 
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Figure 5.2 Acyl-loop in wild type hCE1.  The 15-residue acyl-binding loop is 
positioned above the active site (red inset) and may regulate access into this cavity.  This 
loop is found in all liver CEs, but not in serum or human intestinal enzymes.   
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Figure 5.3 Homology model of rsCE.  Rat serum carboxylesterase (rsCE) does not 
contain the 15-residue acyl loop (yellow) found in hCE1.  Without this loop, the rsCE 
active site (red) is more open.     
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Table 5.1 Custom designed primers for hCE1 LD mutants.  Based on sequence 
alignments between hCE1 and rsCE custom primers were designed to excise the acyl-
loop and include the rsCE linker.  Further mutations were engineered that altered the 
hCE1 active site to mirror respective amino acids in rsCE.    
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Table 5.2 Effects of LD mutations on various CE substrates.  By removing the 15-
residue acyl-loop and mutating the hCE1 active site, activity towards conventional 
carboxylesterase substrates was decreased while hydrolysis of SN-38 enhanced 60-fold.  
N.D. is no detected.   
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Figure 5.4 Homology model of hCE1 LD4 with CPT-11.  By removing the acyl-
binding loop and adding a patch of polar residues (N254 and N388, green inset) near the 
enzyme’s “side-door”, we enhanced the hydrolysis of CPT-11 up to 60-fold over wild 
type hCE1.  These structural features are also found in hiCE and rsCE.   
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